137 results on '"Moon-Gi Choi"'
Search Results
2. Adult Multisystem Langerhans Cell Histiocytosis Presenting with Central Diabetes Insipidus Successfully Treated with Chemotherapy
- Author
-
Jung-Eun Choi, Hae Ri Lee, Jung Hun Ohn, Min Kyong Moon, Juri Park, Seong Jin Lee, Moon-Gi Choi, Hyung Joon Yoo, Jung Han Kim, and Eun-Gyoung Hong
- Subjects
Histiocytosis, Langerhans-cell ,Drug therapy ,Diabetes insipidus ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
We report the rare case of an adult who was diagnosed with recurrent multisystem Langerhans cell histiocytosis (LCH) involving the pituitary stalk and lung who present with central diabetes insipidus and was successfully treated with systemic steroids and chemotherapy. A 49-year-old man visited our hospital due to symptoms of polydipsia and polyuria that started 1 month prior. Two years prior to presentation, he underwent excision of right 6th and 7th rib lesions for the osteolytic lesion and chest pain, which were later confirmed to be LCH on pathology. After admission, the water deprivation test was done and the result indicated that he had central diabetes insipidus. Sella magnetic resonance imaging showed a mass on the pituitary stalk with loss of normal bright spot at the posterior lobe of the pituitary. Multiple patchy infiltrations were detected in both lung fields by computed tomography (CT). He was diagnosed with recurrent LCH and was subsequently treated with inhaled desmopressin, systemic steroids, vinblastine, and mercaptopurine. The pituitary mass disappeared after two months and both lungs were clear on chest CT after 11 months. Although clinical remission in multisystem LCH in adults is reportedly rare, our case of adult-onset multisystem LCH was treated successfully with systemic chemotherapy using prednisolone, vinblastine, and 6-mercaptopurine, which was well tolerated.
- Published
- 2014
- Full Text
- View/download PDF
3. Cardiac Effects of Thyrotropin Oversuppression with Levothyroxine in Young Women with Differentiated Thyroid Cancer
- Author
-
Kyung-Soon Hong, Jung-Woo Son, Ohk Hyun Ryu, Moon-Gi Choi, Ji Yeon Hong, and Seong Jin Lee
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background. We investigated the cardiac effects of TSH (thyroid-stimulating hormone) oversuppression in women with thyroidectomized differentiated thyroid cancer (DTC) during levothyroxine suppression therapy. Methods. Fourteen young female patients with DTC were enrolled. The duration of TSH-suppressive therapy was 5 to 9 years. They satisfied the following criteria: (1) a serum level of TSH < 0.1 mU/L in the intermediate-risk or TSH < 0.3 mU/L in the low-recurrence-risk group and (2) having been receiving a fixed dose of LT4 before the study. Controls matched for age, sex, and body mass index (BMI) were compared in terms of the levels of serum free T4, free T3, TSH, plasma N-terminal pro-brain natriuretic peptide (NT-pro-BNP), and cardiac functions and structures. Results. DTC patients and control subjects were well matched in heart rate and blood pressure. There were marked differences in serum TSH (P=0.001) and free T4 (P=0.002). However, there were no differences between the groups in serum free T3 and plasma NT-pro-BNP. Furthermore, there were nonsignificant differences in cardiac functions and structures between the groups. Conclusions. This study shows that TSH suppression therapy in women with DTC may be safe with respect to cardiac functions and structures despite intermittent oversuppression of TSH during long-term suppressive therapy. Trial Registration. This trial is registered with clinicaltrials.gov identifier NCT02645786.
- Published
- 2016
- Full Text
- View/download PDF
4. Association between Visit-to-Visit Glucose Variability and Cognitive Function in Aged Type 2 Diabetic Patients: A Cross-Sectional Study.
- Author
-
Chulho Kim, Jong-Hee Sohn, Min Uk Jang, Sung-Hun Kim, Moon-Gi Choi, Ohk-Hyun Ryu, Sungwha Lee, and Hui-Chul Choi
- Subjects
Medicine ,Science - Abstract
Diabetes is associated with cognitive decline as well as the development of dementia. Although mean blood glucose levels are typically used to assess the status of diabetic patients, glucose variability is also involved in the manifestation of macro- and microvascular complications in this population. Thus, the present study sought to determine whether visit-to-visit glucose variability contributes to cognitive decline in patients with type 2 diabetes.The present study assessed 68 patients with type 2 diabetes using several validated neuropsychological measures. All patients had no cerebrovascular disease, history of hypoglycemia, psychiatric conditions, or other medical illnesses. Standard deviations (SDs) and coefficients of variance (CVs) of the patients' blood glucose (after fasting and 2 hours postprandial; FBS and PP2), and glycated hemoglobin (HbA1c) values were used as indices of glucose variability. The cognitive outcome parameters were transformed with z-scores and entered into a multiple linear regression model that included educational status, age, sex, vascular risk factors, and mean glucose parameters as covariates.The mean age of the total patient population was 70.9 years; 46 (67.6%) of the patients were men, and the median follow-up duration at our endocrinology outpatient clinic was 4.8 years. The mean FBS and PP2 glucose levels of the patients were 132 mg/dL and 199 mg/dL, respectively, and the mean HbA1c level was 8.0%. A univariable analysis revealed that only the PP2 value was associated with the Mini-Mental State Examination (MMSE) score, and multivariable analysis revealed that a high SD and/or CV for PP2 glucose were associated with low scores on the Rey Complex Figure Copy test and/or the Verbal Learning Test. Additionally, a high SD and a higher CV for HbA1c level were significantly associated with low MMSE and Digit Span test scores even after adjusting for mean HbA1c values.The present data indicate that a greater degree of visit-to-visit glucose variability influenced specific types of cognitive function in type 2 diabetic patients independently of mean blood glucose levels. Future studies should focus on whether reductions in glycemic variability will improve the cognitive decline observed in type 2 diabetic patients.
- Published
- 2015
- Full Text
- View/download PDF
5. In Memoriam
- Author
-
Moon-Gi Choi
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Published
- 2014
- Full Text
- View/download PDF
6. Sinus lifts in the presence of pseudoantral and mucous retention cysts
- Author
-
Moon Gi Choi, Chang Hyun Hong, Eun Joo Choi, Won Jong Park, Young Geun Kim, and Do Geon Gil
- Subjects
Surgery ,Oral Surgery - Published
- 2022
- Full Text
- View/download PDF
7. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study
- Author
-
Young Sik Kim, Tae Ho Kim, Eun Jung Kyung, Kwan Woo Lee, Yeo Kyeong Kim, Soo Kyoung Kim, Jae Myung Yu, Hae Jin Kim, Kyu Jeung Ahn, Ji Hyun Lee, Chang Beom Lee, Moon Gi Choi, Kyung Wan Min, and Hyuk Jae Chang
- Subjects
medicine.medical_specialty ,endocrine system diseases ,business.industry ,Endocrinology, Diabetes and Metabolism ,nutritional and metabolic diseases ,Diabetes mellitus, type 2 ,Type 2 diabetes ,Teneligliptin ,medicine.disease ,Gastroenterology ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,Clinical endpoint ,Medicine ,Population study ,business ,Adverse effect ,Dipeptidyl peptidase-4 ,medicine.drug ,Glycemic ,Original Research ,Dipeptidyl peptidase IV inhibitors - Abstract
Introduction The aim of this study was to assess the efficacy and safety of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite treatment with a stable dose of other DPP-4 inhibitors. Methods Patients with glycosylated hemoglobin (HbA1c) ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other antidiabetic agents, for at least 3 months were enrolled in this study. Patients on DPP-4 inhibitors administered prior to participation in this study were switched to 20 mg teneligliptin once daily and the dose was maintained for the 52-week study period. The primary endpoint was the change in HbA1c at week 12. Fasting plasma glucose (FPG) and the blood lipid profile were also evaluated. Adverse events were monitored for safety assessment. Results At weeks 12, 24, and 52, the HbA1c values significantly decreased by − 0.39, − 0.44, and − 0.52%, respectively, compared to the baseline value (p
- Published
- 2021
8. Temporomandibular joint reconstruction with costochondral graft: case series study
- Author
-
Moon Gi Choi
- Subjects
medicine.medical_specialty ,Autogenous graft ,business.industry ,Case Report ,030206 dentistry ,medicine.disease ,Temporomandibular joint ,Condyle ,Surgery ,03 medical and health sciences ,surgical procedures, operative ,0302 clinical medicine ,medicine.anatomical_structure ,medicine ,Oral Surgery ,Foreign body ,Costochondral graft ,030223 otorhinolaryngology ,business ,Case series - Abstract
Various techniques have been used to reconstruct the temporomandibular joints, including autogenous transplants and alloplastic implants. Among autogenous grafts, costochondral grafts have mainly been used. A costochondral graft has many advantages over other autogenous grafts and alloplastic implants. Harvest is easy and has minimal impact on patients. The graft can bear functional load well and biocompatibility is excellent. A costochondral graft obviates foreign body reactions and further surgery for revision of alloplastic replacements if the graft takes well. Although long-term prognosis remains unclear, it appears that for autogenous condylar reconstruction, costochondral grafts can be used with few complications and acceptable results. This article describes cases and discusses surgical techniques and considerations related to costochondral grafts.
- Published
- 2021
- Full Text
- View/download PDF
9. Case report of the management of the ranula
- Author
-
Moon-Gi Choi
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Plunging ranula ,Sublingual gland ,Case Report ,Ranula ,medicine.disease ,Marsupialization ,Surgery ,medicine.anatomical_structure ,stomatognathic system ,Incision and drainage ,Mylohyoid muscle ,Sclerotherapy ,medicine ,Mucocele ,Oral Surgery ,business - Abstract
Ranula is a mucocele caused by extravasation of the sublingual gland on the floor of the mouth. The most common presentation is a cystic mass in the floor of the mouth. A portion of the sublingual gland could herniate through the mylohyoid muscle, and its extravasated mucin can spread along this hiatus into submandibular and submental spaces and cause cervical swelling. This phenomenon is called plunging ranula. A variety of treatments for ranula has been suggested and include aspiration of cystic fluid, sclerotherapy, marsupialization, incision and drainage, ranula excision only, and excision of the sublingual gland with or without ranula. Those various treatments have shown diverse results. Most surgeons agree that removal of the sublingual gland is necessary in oral and plunging ranula. Four patients with ranula were investigated retrospectively, and treatment methods based on literature review were attempted.
- Published
- 2019
10. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
- Author
-
Kyu Jeung Ahn, Ji Hyun Lee, Young Sik Kim, Soo Kyoung Kim, Kyoung Min Kim, Kwan Woo Lee, Jae Myung Yu, Hae Jin Kim, Chang Beom Lee, Tae Ho Kim, Hyuk Jae Chang, and Moon Gi Choi
- Subjects
Dipeptidyl-peptidase IV inhibitors ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Blood lipids ,030209 endocrinology & metabolism ,Teneligliptin ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus, Type 2 ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,Clinical endpoint ,medicine ,Dipeptidyl peptidase-4 ,Original Research ,Glycemic ,business.industry ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,medicine.disease ,business ,medicine.drug - Abstract
Introduction Teneligliptin, an antidiabetic agent classified as a class III dipeptidyl peptidase-4 (DPP-4) inhibitor, has a unique structural feature that provides strong binding to DPP-4 enzymes. We investigated the efficacy and safety of switching patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control on a stable dose of other DPP-4 inhibitors to teneligliptin. Methods Patients with T2DM whose glycosylated hemoglobin (HbA1c) levels were ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other hypoglycemic agents, for at least 3 months were enrolled. The DPP-4 inhibitors taken before participating in the study were switched to 20 mg qd teneligliptin, and this was to be maintained for 52 weeks. The primary end point was the change in HbA1c levels after 12 weeks. Metabolic parameters including fasting plasma glucose (FPG) and blood lipids were assessed also. To assess safety, adverse and hypoglycemic events were monitored. The data from baseline to week 12 were used for analysis in this interim report. Results The mean change in HbA1c levels from baseline to week 12 was − 0.44%. At week 12, the percentage of patients achieving HbA1c
- Published
- 2019
- Full Text
- View/download PDF
11. Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells
- Author
-
Moon Gi Choi, Yun Kyung Cho, Jun Goo Kang, Sung-Hee Ihm, Seong Jin Lee, Si Hyoung Kim, and Ji Hye Huh
- Subjects
Cancer Research ,Indazoles ,Cell Survival ,Pyridines ,Glycine ,Apoptosis ,Hsp90 inhibitor ,Thyroid carcinoma ,Heat shock protein ,Cell Line, Tumor ,Cytotoxic T cell ,Humans ,Viability assay ,HSP90 Heat-Shock Proteins ,Thyroid Neoplasms ,Extracellular Signal-Regulated MAP Kinases ,Protein kinase B ,Bcl-2-Like Protein 11 ,Chemistry ,Adenine ,General Medicine ,Isoxazoles ,Resorcinols ,Oncology ,Cancer cell ,Benzamides ,Cancer research ,Proto-Oncogene Proteins c-akt ,Signal Transduction - Abstract
BACKGROUND/AIM Heat shock protein 90 (HSP90) controls maturation of oncogenic client proteins of cancer cells, and thus we studied the effect of HSP 90 inhibitors on cell survival and survival-related mediators in thyroid carcinoma cells. MATERIALS AND METHODS Human TPC-1 and SW1736 thyroid carcinoma cells were utilized. Cell viability, cytotoxic activity and apoptosis were estimated using CCK-8 assay, cytotoxicity assay and FACS analysis, respectively. RESULTS AUY922, BIIB021 and SNX5422 decreased cell viability, and increased cytotoxic activity and the proportion of apoptotic cells. The protein levels of cleaved PARP, cleaved caspase-3, Bax and Bim were elevated, and Bcl2 protein levels were reduced. Knockdown of Bax did not change cell viability, cytotoxic activity, the proportion of apoptotic cells and cleaved caspase-3 protein levels. Meanwhile, knockdown of Bim enhanced cell viability, and diminished cytotoxic activity, the proportion of apoptotic cells and cleaved caspase-3 protein levels. AUY922, BIIB021 and SNX5422 increased the protein levels of phospho-AMPK, and decreased those of phospho-ERK1/2, and total and phospho-AKT. CONCLUSION AUY922, BIIB021 and SNX5422 induce cytotoxicity by modulating Bim and ERK1/2, AKT and AMPK signaling in thyroid carcinoma cells.
- Published
- 2020
12. Evodiamine Suppresses Survival, Proliferation, Migration and Epithelial–Mesenchymal Transition of Thyroid Carcinoma Cells
- Author
-
Moon Gi Choi, Jun Goo Kang, Si Hyoung Kim, Sung-Hee Ihm, Seong Jin Lee, and Chul Sik Kim
- Subjects
0301 basic medicine ,Cancer Research ,Epithelial-Mesenchymal Transition ,Cell Survival ,Antineoplastic Agents ,Vimentin ,Thyroid carcinoma ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Movement ,Evodiamine ,Cell Line, Tumor ,Humans ,Cytotoxic T cell ,Thyroid Neoplasms ,Viability assay ,Epithelial–mesenchymal transition ,Phosphorylation ,Protein kinase B ,Cell Proliferation ,biology ,Drug Synergism ,General Medicine ,Androstadienes ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Proto-Oncogene Proteins c-bcl-2 ,Oncology ,chemistry ,Apoptosis ,030220 oncology & carcinogenesis ,Quinazolines ,Cancer research ,biology.protein ,Wortmannin ,Proto-Oncogene Proteins c-akt ,Signal Transduction - Abstract
Background/aim The aim of this study was to evaluate the effect of evodiamine alone or in combination with chemotherapeutic agents on thyroid carcinoma cells. Materials and methods TPC-1 and SW1736 thyroid carcinoma cells were used. Cell viability, cytotoxic activity, apoptosis and migration were examined by applying appropriate methods. Drug combination analysis was performed. Results Evodiamine treatment of cells decreased cell viability, and Bcl2 and phospho-AKT protein levels. Cytotoxic activity and the percentage of apoptotic cells increased. After co-treatment of wortmannin, cell viability, and phospho-AKT and Bcl2 protein levels decreased, and cytotoxic activity increased. In transforming growth factor-β-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased β-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels. When cells were treated with both evodiamine and chemotherapeutic agents, all combination index values were lower than 1.0. Conclusion Evodiamine was cytotoxic towards thyroid carcinoma cells, and repression of AKT reinforced evodiamine-induced cytotoxicity. Furthermore, evodiamine ameliorated proliferation, migration and epithelial-mesenchymal transition, and synergized with chemotherapeutic agents.
- Published
- 2018
- Full Text
- View/download PDF
13. Enigma Plays Roles in Survival of Thyroid Carcinoma Cells through PI3K/AKT Signaling and Survivin
- Author
-
H. Hwang, Yoon Jung Kim, Moon Gi Choi, Sung-Hee Ihm, Seong Jin Lee, Jun Goo Kang, and Chul Sik Kim
- Subjects
Cyclin-Dependent Kinase Inhibitor p21 ,0301 basic medicine ,Cancer Research ,Cell Survival ,Survivin ,Inhibitor of Apoptosis Proteins ,Thyroid carcinoma ,Phosphatidylinositol 3-Kinases ,03 medical and health sciences ,Cell Movement ,Cell Line, Tumor ,Humans ,Cytotoxic T cell ,Thyroid Neoplasms ,Viability assay ,Protein kinase B ,Adaptor Proteins, Signal Transducing ,Cell Proliferation ,Cell growth ,Chemistry ,Cell migration ,General Medicine ,Transfection ,LIM Domain Proteins ,Cytoskeletal Proteins ,030104 developmental biology ,Matrix Metalloproteinase 9 ,Oncology ,Cancer research ,Matrix Metalloproteinase 2 ,RNA Interference ,Poly(ADP-ribose) Polymerases ,Tumor Suppressor Protein p53 ,Proto-Oncogene Proteins c-akt ,Signal Transduction - Abstract
Background/aim The aim of the present study was to assess the role of enigma protein in survival of thyroid carcinoma cells. Materials and methods BCPAP and 8505C human thyroid carcinoma cells were used. Cell viability using CCK-8 assay, the percentage of dead cells using trypan blue assay, cytotoxic activity using cytotoxicity assay, cell growth rate and cell migration using wound-healing assay were performed. Results In enigma siRNA-transfected cells, cell viability, and the protein levels of AKT and survivin decreased. The percentage of dead cells, cytotoxic activity and cleaved poly (ADP-ribose) polymerase (PARP) protein levels increased. After transfection of p110α plasmid, the alterations in cell viability, the percentage of dead cells, cytotoxic activity, and protein levels of AKT, survivin and cleaved PARP were abrogated. Cell growth rate and cell migration were reduced with reduction of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) protein levels, as well as increased p53 and p21 protein levels. Conclusion Enigma affects cell survival through modulation of phosphatidylinositol-3 kinase/AKT signaling and survivin, and regulates cell proliferation and migration via involvement of MMP-2, MMP-9, p53 and p21 in thyroid carcinoma cells.
- Published
- 2018
- Full Text
- View/download PDF
14. Modified drainage of submasseteric space abscess
- Author
-
Moon-Gi Choi
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine.disease ,Trismus ,Submasseteric space ,Facial nerve ,030218 nuclear medicine & medical imaging ,Surgery ,Modified drainage ,03 medical and health sciences ,Dissection ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Incision and drainage ,medicine ,Technical Note ,Local anesthesia ,Submasseteric space abscess ,Oral Surgery ,Drainage ,medicine.symptom ,Abscess ,business - Abstract
Once a submasseteric space infection is diagnosed, the key to resolving the infection is via surgical intervention to evacuate the pus. Although it is possible and occasionally practical to drain the submasseteric space via an intraoral approach, an extraoral approach may sometimes be required. Surgeons have encountered complications such as facial nerve damage during extraoral incision and drainage procedures, and they have felt that extraoral dissection was very difficult. As such, an easier and simpler technique is needed. Our department recently modified various drainage techniques for submasseteric space abscesses. Damage to the marginal branch of the facial nerve did not occur, and this technique was very simple and rapid, such that a novice physician could perform this procedure. This modified technique was possible with trismus and under local anesthesia. After intraorally checking the position of the drain, the intraoral wound is closed with an absorbable suture and the drain is fixed to the extraoral skin. When a masseteric space infection is diagnosed, multiple space involvement is ruled out, and dependent drainage is required, this modified drainage technique can be useful.
- Published
- 2017
15. Ancient Schwannoma Arising in Masseter Muscle: A Case Report
- Author
-
Yeong-Kon Jeong, Won-Jong Park, Eun Joo Choi, Il-Kyung Park, Moon-Gi Choi, and Kyung-Hwan Kwon
- Subjects
Masseter muscle ,Neurilemoma ,business.industry ,Medicine ,Anatomy ,business - Published
- 2017
- Full Text
- View/download PDF
16. Correlations between anatomic variations of maxillary sinus ostium and postoperative complication after sinus lifting
- Author
-
Seung Jae Paek, Ji Yong Yoo, Eun Joo Choi, Moon Gi Choi, Jang Won Lee, Kyung-Hwan Kwon, and Won Jong Park
- Subjects
Sinus Floor Augmentation ,medicine.medical_specialty ,Maxillary sinus ,03 medical and health sciences ,0302 clinical medicine ,Maxillary sinusitis ,medicine ,otorhinolaryngologic diseases ,Ostio-meatal complex ,030223 otorhinolaryngology ,Sinusitis ,Sinus (anatomy) ,business.industry ,fungi ,Ethmoidectomy ,food and beverages ,Postoperative complication ,030206 dentistry ,medicine.disease ,Surgery ,Ostium ,medicine.anatomical_structure ,Anatomic variation ,Original Article ,Oral Surgery ,business ,Complication ,Sinus floor augmentation - Abstract
Objectives The maxillary sinus mucosa is reported to recover to preoperative sterility after sinus floor elevation. However, when drainage of maxillary sinus is impaired, recovery can be delayed and maxillary sinusitis can occur. Therefore, in this study, we investigated the correlations between anatomic variants that can interrupt the ostium of the maxillary sinus and incidence of complication after sinus lifting. Materials and Methods The subjects are 81 patients who underwent sinus lifting in Wonkwang University Dental Hospital (Iksan, Korea). Computed tomography (CT) images of the subjects were reviewed for presence of nasal septum deviation, anatomic variants of the middle turbinate, and Haller cells. Correlations between anatomic variations and occurrence of maxillary sinusitis were statistically analyzed. Results Patients with anatomic variants of ostio-meatal units, such as deviated nasal septum, concha bullosa or paradoxical curvature of the middle turbinate, or Haller cells, showed a higher rate of complication. However, only presence of Haller cell showed statistically significant. Conclusion Before sinus lifting, CT images are recommended to detect anatomic variants of the ostio-meatal complex. If disadvantageous anatomic variants are detected, the use of nasal decongestants should be considered to reduce the risk of postoperative sinusitis.
- Published
- 2016
17. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- Author
-
Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Joel Z Melnick, Michael G Miller, Pablo E Pergola, Vlado Perkovic, Sheldon Tobe, Tingting Yi, Melissa Wigderson, Dick de Zeeuw, Alicia Elbert, Augusto Vallejos, Andres Alvarisqueta, Laura Maffei, Luis Juncos, Javier de Arteaga, Gustavo Greloni, Eduardo Farias, Alfredo Zucchini, Daniel Vogel, Ana Cusumano, Juan Santos, Margaret Fraenkel, Martin Gallagher, Tim Davis, Shamasunder Acharya, Duncan Cooke, Michael Suranyi, Simon Roger, Nigel Toussaint, Carol Pollock, Doris Chan, Stephen Stranks, Richard MacIsaac, Zoltan Endre, Alice Schmidt, Rudolf Prager, Gert Mayer, Xavier Warling, Michel Jadoul, Jean Hougardy, Chris Vercammen, Bruno Van Vlem, Pieter Gillard, Adriana Costa e Forti, Joao Lindolfo Borges, Luis Santos Canani, Freddy Eliaschewitz, Silmara Leite, Fadlo Fraige Filho, Raphael Paschoalin, Jose Andrade Moura Neto, Luciane Deboni, Irene de Lourdes Noronha, Cintia Cercato, Carlos Alberto Prompt, Maria Zanella, Nelson Rassi, Domingos D'Avila, Rosangela Milagres, Joao Felicio, Roberto Pecoits Filho, Miguel Carlos Riella, Joao Salles, Elizete Keitel, Sergio Draibe, Celso Amodeo, Joseph Youmbissi, Louise Roy, Serge Cournoyer, Shivinder Jolly, Vincent Pichette, Gihad Nesrallah, Harpreet Singh Bajaj, Hasnain Khandwala, Ronnie Aronson, Richard Goluch, Paul Tam, Christian Rabbat, Gordon Bailey, Stephen Chow, Alvaro Castillo, Alfredo Danin Vargas, Fernando Gonzalez, Rodrigo Munoz, Vicente Gutierrez, Gonzalo Godoy, Hongwen Zhao, Zhangsuo Liu, Minghui Zhao, Xiaohui Guo, Benli Su, Shuxia Fu, Yan Xu, Jinkui Yang, Bingyin Shi, Guanqing Xiao, Wei Shi, Chuanming Hao, Changying Xing, Fanfan Hou, Qun Luo, Yuxiu Li, Linong Ji, Li Zuo, Song Wang, Zhaohui Ni, Guohua Ding, Nan Chen, Jiajun Zhao, Weiping Jia, Shengqiang Yu, Jian Weng, Gang Xu, Ping Fu, Shiren Sun, Bicheng Liu, Xiaoqiang Ding, Ivan Rychlik, Alexandra Oplustilova, Dagmar Bartaskova, Vaclava Honova, Hana Chmelickova, Martin Petr, Petr Bucek, Vladimir Tesar, Emil Zahumensky, Johan Povlsen, Kenneth Egstrup, Anna Oczachowska-Kulik, Peter Rossing, Jorma Lahtela, Jorma Strand, Ilkka Kantola, Catherine Petit, Christian Combe, Philippe Zaoui, Vincent Esnault, Pablo Urena Torres, Jean-Michel Halimi, Bertrand Dussol, Tasso Bieler, Klemens Budde, Frank Dellanna, Thomas Segiet, Christine Kosch, Hans Schmidt-Guertler, Isabelle Schenkenberger, Volker Vielhauer, Frank Pistrosch, Mark Alscher, Christoph Hasslacher, Christian Hugo, Anja Muehlfeld, Christoph Wanner, Ploumis Passadakis, Theofanis Apostolou, Nikolaos Tentolouris, Ioannis Stefanidis, Konstantinos Mavromatidis, Vasilios Liakopoulos, Dimitrios Goumenos, Konstantinos Siamopoulos, Vincent Yeung, Risa Ozaki, Samuel Fung, Kathryn Tan, Sydney Tang, Sing Leung Lui, Siu Fai Cheung, Seamus Sreenan, Joseph Eustace, Donal O'Shea, Peter Lavin, Austin Stack, Yoram Yagil, Julio Wainstein, Hilla Knobler, Josef Cohen, Irina Kenis, Deeb Daoud, Yosefa Bar-Dayan, Victor Frajewicki, Faiad Adawi, Loreto Gesualdo, Domenico Santoro, Francesco Marino, Andrea Galfre, Chiara Brunati, Piero Ruggenenti, Giuseppe Rombola, Giuseppe Pugliese, Maura Ravera, Fabio Malberti, Giuseppe Pontoriero, Teresa Rampino, Salvatore De Cosmo, Ciro Esposito, Felice Nappi, Cataldo Abaterusso, Giuseppe Conte, Vincenzo Panichi, Davide Lauro, Giovambattista Capasso, Domenico Russo, Jiichi Anzai, Motoji Naka, Keita Ato, Tetsuro Tsujimoto, Toshinori Nimura, Eitaro Nakashima, Tetsuro Takeda, Shinya Fujii, Kunihisa Kobayashi, Hideaki Iwaoka, Koji Nagayama, Hiroyuki Harada, Hajime Maeda, Rui Kishimoto, Tadashi Iitsuka, Naoki Itabashi, Ryuichi Furuya, Yoshitaka Maeda, Daishiro Yamada, Nobuhiro Sasaki, Hiromitsu Sasaki, Shinichiro Ueda, Naoki Kashihara, Shuichi Watanabe, Takehiro Nakamura, Hidetoshi Kanai, Yuichiro Makita, Keiko Ono, Noriyuki Iehara, Daisuke Goto, Keiichiro Kosuge, Kenichi Tsuchida, Toshiaki Sato, Takashi Sekikawa, Hideki Okamoto, Tsuyoshi Tanaka, Naoko Ikeda, Takenobu Tadika, Koji Mukasa, Takeshi Osonoi, Fuminori Hirano, Motonobu Nishimura, Yuko Yambe, Yukio Tanaka, Makoto Ujihara, Takashi Sakai, Mitsuo Imura, Yutaka Umayahara, Shinya Makino, Jun Nakazawa, Yukinari Yamaguchi, Susumu Kashine, Hiroaki Miyaoka, Katsunori Suzuki, Toshihiko Inoue, Sou Nagai, Nobuyuki Sato, Masahiro Yamamoto, Noriyasu Taya, Akira Fujita, Akira Matsutani, Yugo Shibagaki, Yuichi Sato, Akira Yamauchi, Masahiro Tsutsui, Tamayo Ishiko, Shizuka Kaneko, Nobuyuki Azuma, Hirofumi Matsuda, Yasuhiro Hashiguchi, Yukiko Onishi, Mikiya Tokui, Munehide Matsuhisa, Arihiro Kiyosue, Junji Shinoda, Kazuo Ishikawa, Ghazali Ahmad, Shalini Vijayasingham, Nor Azizah Aziz, Zanariah Hussein, Yin Khet Fung, Wan Hasnul Halimi Wan Hassan, Hin Seng Wong, Bak Leong Goh, Norhaliza Mohd Ali, Nor Shaffinaz Yusuf Azmi Merican, Indralingam Vaithilingam, Nik Nur Fatnoon Nik Ahmad, Noor Adam, Norlela Sukor, V Paranthaman P Vengadasalam, Khalid Abdul Kadir, Mafauzy Mohamed, Karina Renoirte Lopez, Aniceto Leguizamo-Dimas, Alfredo Chew Wong, Jose Chevaile-Ramos, Jose Gonzalez Gonzalez, Raul Rico Hernandez, Jose Nino-Cruz, Leobardo Sauque Reyna, Guillermo Gonzalez-Galvez, Magdalena Madero Rovalo, Tomasso Bochicchio-Ricardelli, Jorge Aldrete, Jaime Carranza-Madrigal, Liffert Vogt, Peter Smak Gregoor, JNM Barendregt, Peter Luik, Ronald Gansevoort, Gozewijn Laverman, Helen Pilmore, Helen Lunt, John Baker, Steven Miller, Kannaiyan Rabindranath, Luis Zapata-Rincon, Rolando Vargas-Gonzales, Jorge Calderon Ticona, Augusto Dextre Espinoza, Jose Burga Nunez, Carlos Antonio Zea-Nunez, Benjamin Herrada Orue, Boris Medina-Santander, Cesar Delgado-Butron, Julio Farfan-Aspilcueta, Stanislaw Mazur, Miroslaw Necki, Michal Wruk, Katarzyna Klodawska, Grazyna Popenda, Ewa Skokowska, Malgorzata Arciszewska, Andrzej Wiecek, Kazimierz Ciechanowski, Michal Nowicki, Rita Birne, Antonio Cabrita, Aura Ramos, Manuel Anibal Antunes Ferreira, Evelyn Matta Fontanet, Altagracia Aurora Alcantara-Gonzalez, Angel Comulada-Rivera, Eugenia Galindo Ramos, Jose Cangiano, Luis Quesada-Suarez, Ricardo Calderon Ortiz, Jose Vazquez-Tanus, Rafael Burgos-Calderon, Carlos Rosado, Nicolae Hancu, Ella Pintilei, Cristina Mistodie, Gabriel Bako, Lavinia Ionutiu, Ligia Petrica, Romulus Timar, Liliana Tuta, Livia Duma, Adriana Tutescu, Svetlana Ivanova, Ashot Essaian, Konstantin Zrazhevskiy, Natalia Tomilina, Elena Smolyarchuk, Anatoly Kuzin, Olga Lantseva, Irina Karpova, Minara Shamkhalova, Natalia Liberanskaya, Andrey Yavdosyuk, Yuri Shvarts, Tatiana Bardymova, Olga Blagoveshchenskaya, Oleg Solovev, Elena Rechkova, Natalia Pikalova, Maria Pavlova, Elena Kolmakova, Rustam Sayfutdinov, Svetlana Villevalde, Natalya Koziolova, Vladimir Martynenko, Vyacheslav Marasaev, Adelya Maksudova, Olga Sigitova, Viktor Mordovin, Vadim Klimontov, Yulia Samoylova, Tatiana Karonova, Lee Ying Yeoh, Boon Wee Teo, Marjorie Wai Yin Foo, Adrian Liew, Ivan Tkac, Aniko Oroszova, Jozef Fekete, Jaroslav Rosenberger, Ida Obetkova, Alla Fulopova, Eva Kolesarova, Katarina Raslova, Peter Smolko, Adrian Oksa, Larry Distiller, Julien Trokis, Luthando Adams, Hemant Makan, Padaruth Ramlachan, Essack Mitha, Kathleen Coetzee, Zelda Punt, Qasim Bhorat, Puvenesvari Naiker, Graham Ellis, Louis Van Zyl, Kwan Woo Lee, Min Seon Kim, Soon-Jib Yoo, Kun Ho Yoon, Yong-Wook Cho, Tae-Sun Park, Sang Yong Kim, Moon-Gi Choi, Tae Keun Oh, Kang-Wook Lee, Ho Sang Shon, Sung Hwan Suh, Byung-Joon Kim, Kim Doo-Man, Joo Hark Yi, Sang Ah Lee, Ho Chan Cho, Sin-Gon Kim, Dae-Ryong Cha, Ji A Seo, Kyung Mook Choi, Jeong-Taek Woo, Kyu Jeung Ahn, Jae Hyuk Lee, In-Joo Kim, Moon-Kyu Lee, Hak Chul Jang, Kyong-Soo Park, Beom Seok Kim, Ji Oh Mok, Mijung Shin, Sun Ae Yoon, Il-Seong Nam-Goong, Choon Hee Chung, Tae Yang Yu, Hyoung Woo Lee, Alfonso Soto Gonzalez, Jaume Almirall, Jesus Egido, Francesca Calero Gonzalez, Gema Fernandez Fresnedo, Ildefonso Valera Cortes, Manuel Praga Terente, Isabel Garcia Mendez, Juan Navarro Gonzalez, Jose Herrero Calvo, Secundino Cigarran Guldris, Mario Prieto Velasco, Jose Ignacio Minguela Pesquera, Antonio Galan, Julio Pascual, Maria Marques Vidas, Judith Martins Munoz, Jose Rodriguez-Perez, Cristina Castro-Alonso, Josep Bonet Sol, Daniel Seron, Elvira Fernandez Giraldez, Javier Arrieta Lezama, Nuria Montero, Julio Hernandez-Jaras, Rafael Santamaria Olmo, Jose Ramon Molas Coten, Olof Hellberg, Bengt Fellstrom, Andreas Bock, Dee Pei, Ching-Ling Lin, Kai-Jen Tien, Ching-Chu Chen, Chien-Ning Huang, Ju-Ying Jiang, Du-An Wu, Chih-Hsun Chu, Shih-Ting Tseng, Jung-Fu Chen, Cho-Tsan Bau, Wayne Sheu, Mai-Szu Wu, Ramazan Sari, Siren Sezer, Alaattin Yildiz, Ilhan Satman, Betul Kalender, Borys Mankovskyy, Ivan Fushtey, Mykola Stanislavchuk, Mykola Kolenyk, Iryna Dudar, Viktoriia Zolotaikina, Orest Abrahamovych, Tetyana Kostynenko, Olena Petrosyan, Petro Kuskalo, Olga Galushchak, Oleg Legun, Ivan Topchii, Liliya Martynyuk, Vasyl Stryzhak, Svitlana Panina, Sergii Tkach, Vadym Korpachev, Peter Maxwell, Luigi Gnudi, Sui Phin Kon, Hilary Tindall, Phillip Kalra, Patrick Mark, Dipesh Patel, Mohamed El-Shahawy, Liqun Bai, Romanita Nica, Yeong-Hau Lien, Judson Menefee, Robert Busch, Alan Miller, Azazuddin Ahmed, Ahmed Arif, Joseph Lee, Sachin Desai, Shweta Bansal, Marie Bentsianov, Mario Belledonne, Charles Jere, Raul Gaona, Gregory Greenwood, Osvaldo Brusco, Mark Boiskin, Diogo Belo, Raffi Minasian, Naveen Atray, Mary Lawrence, John Taliercio, Pablo Pergola, David Scott, German Alvarez, Bradley Marder, Thomas Powell, Wa'el Bakdash, George Stoica, Christopher McFadden, Marc Rendell, Jonathan Wise, Audrey Jones, Michael Jardula, Ivy-Joan Madu, Freemu Varghese, Brian Tulloch, Ziauddin Ahmed, Melanie Hames, Imran Nazeer, Newman Shahid, Rekha John, Manuel Montero, David Fitz-Patrick, Lawrence Phillips, Antonio Guasch, Elena Christofides, Aijaz Gundroo, Mohammad Amin, Cynthia Bowman-Stroud, Michael Link, Laura Mulloy, Michael Nammour, Tarik Lalwani, Lenita Hanson, Adam Whaley-Connell, Lee Herman, Rupi Chatha, Sayed Osama, Kenneth Liss, Zeid Kayali, Anuj Bhargava, Ezra Israel, Alfredo Peguero-Rivera, Michael Fang, Judith Slover, Elena Barengolts, Jose Flores, Rosemary Muoneke, Virginia Savin, Stella Awua-Larbi, Andrew Levine, George Newman, Laden Golestaneh, Guillermo Bohm, Efrain Reisin, Lucita Cruz, Robert Weiss, Franklin Zieve, Edward Horwitz, Peale Chuang, James Mersey, John Manley, Ronald Graf, Fadi Bedros, Sudhir Joshi, Juan Frias, Ali Assefi, Andrew O'Shaughnessy, Roman Brantley, Todd Minga, David Tietjen, Samuel Kantor, Aamir Jamal, Ramon Guadiz, Kenneth Hershon, Peter Bressler, Nelson Kopyt, Harold Cathcart, Scott Bloom, Ronald Reichel, Samer Nakhle, Emily Dulude, Joshua Tarkan, Penelope Baker, Steven Zeig, Jaynier Moya Hechevarria, Armando Ropero-Cartier, Gilda De la Calle, Ankur Doshi, Fadi Saba, Teresa Sligh, Sylvia Shaw, Jayant Kumar, Harold Szerlip, George Bayliss, Alan Perlman, Lakhi Sakhrani, Steven Gouge, Georges Argoud, Idalia Acosta, John Elder, Sucharit Joshi, John Sensenbrenner, Steven Vicks, Roberto Mangoo-Karim, Claude Galphin, Carlos Leon-Forero, John Gilbert, Eric Brown, Adeel Ijaz, Salman Butt, Mariana Markell, Carlos Arauz-Pacheco, Lance Sloan, Odilon Alvarado, Serge Jabbour, Eric Simon, Anjay Rastogi, Sam James, Karen Hall, John Melish, Brad Dixon, Allen Adolphe, Csaba Kovesdy, Srinivasan Beddhu, Richard Solomon, Ronald Fernando, Ellis Levin, Charuhas Thakar, Brooks Robey, David Goldfarb, Linda Fried, Geetha Maddukuri, Stephen Thomson, Andrew Annand, Saeed Kronfli, Paramjit Kalirao, Rebecca Schmidt, Neera Dahl, Samuel Blumenthal, Debra Weinstein, Ove Ostergaard, Talia Weinstein, Yasuhiro Ono, Murat Yalcin, Shahana Karim, APH - Health Behaviors & Chronic Diseases, Nephrology, ACS - Amsterdam Cardiovascular Sciences, ACS - Microcirculation, Biomedical Signals and Systems, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Heerspink, H. J. L., Parving, H. -H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F. -F., Kitzman, D. W., Kohan, D., Makino, H., Mcmurray, J. J. V., Melnick, J. Z., Miller, M. G., Pergola, P. E., Perkovic, V., Tobe, S., Yi, T., Wigderson, M., de Zeeuw, D., Elbert, A., Vallejos, A., Alvarisqueta, A., Maffei, L., Juncos, L., de Arteaga, J., Greloni, G., Farias, E., Zucchini, A., Vogel, D., Cusumano, A., Santos, J., Fraenkel, M., Gallagher, M., Davis, T., Acharya, S., Cooke, D., Suranyi, M., Roger, S., Toussaint, N., Pollock, C., Chan, D., Stranks, S., Macisaac, R., Endre, Z., Schmidt, A., Prager, R., Mayer, G., Warling, X., Jadoul, M., Hougardy, J., Vercammen, C., Van Vlem, B., Gillard, P., Costa e Forti, A., Borges, J. L., Santos Canani, L., Eliaschewitz, F., Leite, S., Fraige Filho, F., Paschoalin, R., Moura Neto, J. A., Deboni, L., de Lourdes Noronha, I., Cercato, C., Prompt, C. A., Zanella, M., Rassi, N., D'Avila, D., Milagres, R., Felicio, J., Pecoits Filho, R., Riella, M. C., Salles, J., Keitel, E., Draibe, S., Amodeo, C., Youmbissi, J., Roy, L., Cournoyer, S., Jolly, S., Pichette, V., Nesrallah, G., Bajaj, H. S., Khandwala, H., Aronson, R., Goluch, R., Tam, P., Rabbat, C., Bailey, G., Chow, S., Castillo, A., Danin Vargas, A., Gonzalez, F., Munoz, R., Gutierrez, V., Godoy, G., Zhao, H., Liu, Z., Zhao, M., Guo, X., Su, B., Fu, S., Xu, Y., Yang, J., Shi, B., Xiao, G., Shi, W., Hao, C., Xing, C., Hou, F., Luo, Q., Li, Y., Ji, L., Zuo, L., Wang, S., Ni, Z., Ding, G., Chen, N., Zhao, J., Jia, W., Yu, S., Weng, J., Xu, G., Fu, P., Sun, S., Liu, B., Ding, X., Rychlik, I., Oplustilova, A., Bartaskova, D., Honova, V., Chmelickova, H., Petr, M., Bucek, P., Tesar, V., Zahumensky, E., Povlsen, J., Egstrup, K., Oczachowska-Kulik, A., Rossing, P., Lahtela, J., Strand, J., Kantola, I., Petit, C., Combe, C., Zaoui, P., Esnault, V., Urena Torres, P., Halimi, J. -M., Dussol, B., Bieler, T., Budde, K., Dellanna, F., Segiet, T., Kosch, C., Schmidt-Guertler, H., Schenkenberger, I., Vielhauer, V., Pistrosch, F., Alscher, M., Hasslacher, C., Hugo, C., Muehlfeld, A., Wanner, C., Passadakis, P., Apostolou, T., Tentolouris, N., Stefanidis, I., Mavromatidis, K., Liakopoulos, V., Goumenos, D., Siamopoulos, K., Yeung, V., Ozaki, R., Fung, S., Tan, K., Tang, S., Lui, S. L., Cheung, S. F., Sreenan, S., Eustace, J., O'Shea, D., Lavin, P., Stack, A., Yagil, Y., Wainstein, J., Knobler, H., Cohen, J., Kenis, I., Daoud, D., Bar-Dayan, Y., Frajewicki, V., Adawi, F., Gesualdo, L., Santoro, D., Marino, F., Galfre, A., Brunati, C., Ruggenenti, P., Rombola, G., Pugliese, G., Ravera, M., Malberti, F., Pontoriero, G., Rampino, T., De Cosmo, S., Esposito, C., Nappi, F., Abaterusso, C., Conte, G., Panichi, V., Lauro, D., Capasso, G., Russo, D., Anzai, J., Naka, M., Ato, K., Tsujimoto, T., Nimura, T., Nakashima, E., Takeda, T., Fujii, S., Kobayashi, K., Iwaoka, H., Nagayama, K., Harada, H., Maeda, H., Kishimoto, R., Iitsuka, T., Itabashi, N., Furuya, R., Maeda, Y., Yamada, D., Sasaki, N., Sasaki, H., Ueda, S., Kashihara, N., Watanabe, S., Nakamura, T., Kanai, H., Makita, Y., Ono, K., Iehara, N., Goto, D., Kosuge, K., Tsuchida, K., Sato, T., Sekikawa, T., Okamoto, H., Tanaka, T., Ikeda, N., Tadika, T., Mukasa, K., Osonoi, T., Hirano, F., Nishimura, M., Yambe, Y., Tanaka, Y., Ujihara, M., Sakai, T., Imura, M., Umayahara, Y., Makino, S., Nakazawa, J., Yamaguchi, Y., Kashine, S., Miyaoka, H., Suzuki, K., Inoue, T., Nagai, S., Sato, N., Yamamoto, M., Taya, N., Fujita, A., Matsutani, A., Shibagaki, Y., Sato, Y., Yamauchi, A., Tsutsui, M., Ishiko, T., Kaneko, S., Azuma, N., Matsuda, H., Hashiguchi, Y., Onishi, Y., Tokui, M., Matsuhisa, M., Kiyosue, A., Shinoda, J., Ishikawa, K., Ahmad, G., Vijayasingham, S., Aziz, N. A., Hussein, Z., Fung, Y. K., Hassan, W. H. H. W., Wong, H. S., Goh, B. L., Ali, N. M., Merican, N. S. Y. A., Vaithilingam, I., Nik Ahmad, N. N. F., Adam, N., Sukor, N., Vengadasalam, V. P. P., Abdul Kadir, K., Mohamed, M., Renoirte Lopez, K., Leguizamo-Dimas, A., Chew Wong, A., Chevaile-Ramos, J., Gonzalez Gonzalez, J., Rico Hernandez, R., Nino-Cruz, J., Sauque Reyna, L., Gonzalez-Galvez, G., Madero Rovalo, M., Bochicchio-Ricardelli, T., Aldrete, J., Carranza-Madrigal, J., Vogt, L., Smak Gregoor, P., Barendregt, J. N. M., Luik, P., Gansevoort, R., Laverman, G., Pilmore, H., Lunt, H., Baker, J., Miller, S., Rabindranath, K., Zapata-Rincon, L., Vargas-Gonzales, R., Calderon Ticona, J., Dextre Espinoza, A., Burga Nunez, J., Zea-Nunez, C. A., Herrada Orue, B., Medina-Santander, B., Delgado-Butron, C., Farfan-Aspilcueta, J., Mazur, S., Necki, M., Wruk, M., Klodawska, K., Popenda, G., Skokowska, E., Arciszewska, M., Wiecek, A., Ciechanowski, K., Nowicki, M., Birne, R., Cabrita, A., Ramos, A., Antunes Ferreira, M. A., Matta Fontanet, E., Alcantara-Gonzalez, A. A., Comulada-Rivera, A., Galindo Ramos, E., Cangiano, J., Quesada-Suarez, L., Calderon Ortiz, R., Vazquez-Tanus, J., Burgos-Calderon, R., Rosado, C., Hancu, N., Pintilei, E., Mistodie, C., Bako, G., Ionutiu, L., Petrica, L., Timar, R., Tuta, L., Duma, L., Tutescu, A., Ivanova, S., Essaian, A., Zrazhevskiy, K., Tomilina, N., Smolyarchuk, E., Kuzin, A., Lantseva, O., Karpova, I., Shamkhalova, M., Liberanskaya, N., Yavdosyuk, A., Shvarts, Y., Bardymova, T., Blagoveshchenskaya, O., Solovev, O., Rechkova, E., Pikalova, N., Pavlova, M., Kolmakova, E., Sayfutdinov, R., Villevalde, S., Koziolova, N., Martynenko, V., Marasaev, V., Maksudova, A., Sigitova, O., Mordovin, V., Klimontov, V., Samoylova, Y., Karonova, T., Yeoh, L. Y., Teo, B. W., Foo, M. W. Y., Liew, A., Tkac, I., Oroszova, A., Fekete, J., Rosenberger, J., Obetkova, I., Fulopova, A., Kolesarova, E., Raslova, K., Smolko, P., Oksa, A., Distiller, L., Trokis, J., Adams, L., Makan, H., Ramlachan, P., Mitha, E., Coetzee, K., Punt, Z., Bhorat, Q., Naiker, P., Ellis, G., Van Zyl, L., Lee, K. W., Kim, M. S., Yoo, S. -J., Yoon, K. H., Cho, Y. -W., Park, T. -S., Kim, S. Y., Choi, M. -G., Oh, T. K., Lee, K. -W., Shon, H. S., Suh, S. H., Kim, B. -J., Doo-Man, K., Yi, J. H., Lee, S. A., Cho, H. C., Kim, S. -G., Cha, D. -R., Seo, J. A., Choi, K. M., Woo, J. -T., Ahn, K. J., Lee, J. H., Kim, I. -J., Lee, M. -K., Jang, H. C., Park, K. -S., Kim, B. S., Mok, J. O., Shin, M., Yoon, S. A., Nam-Goong, I. -S., Chung, C. H., Yu, T. Y., Lee, H. W., Soto Gonzalez, A., Almirall, J., Egido, J., Calero Gonzalez, F., Fernandez Fresnedo, G., Valera Cortes, I., Praga Terente, M., Garcia Mendez, I., Navarro Gonzalez, J., Herrero Calvo, J., Cigarran Guldris, S., Prieto Velasco, M., Minguela Pesquera, J. I., Galan, A., Pascual, J., Marques Vidas, M., Martins Munoz, J., Rodriguez-Perez, J., Castro-Alonso, C., Bonet Sol, J., Seron, D., Fernandez Giraldez, E., Arrieta Lezama, J., Montero, N., Hernandez-Jaras, J., Santamaria Olmo, R., Molas Coten, J. R., Hellberg, O., Fellstrom, B., Bock, A., Pei, D., Lin, C. -L., Tien, K. -J., Chen, C. -C., Huang, C. -N., Jiang, J. -Y., Wu, D. -A., Chu, C. -H., Tseng, S. -T., Chen, J. -F., Bau, C. -T., Sheu, W., Wu, M. -S., Sari, R., Sezer, S., Yildiz, A., Satman, I., Kalender, B., Mankovskyy, B., Fushtey, I., Stanislavchuk, M., Kolenyk, M., Dudar, I., Zolotaikina, V., Abrahamovych, O., Kostynenko, T., Petrosyan, O., Kuskalo, P., Galushchak, O., Legun, O., Topchii, I., Martynyuk, L., Stryzhak, V., Panina, S., Tkach, S., Korpachev, V., Maxwell, P., Gnudi, L., Kon, S. P., Tindall, H., Kalra, P., Mark, P., Patel, D., El-Shahawy, M., Bai, L., Nica, R., Lien, Y. -H., Menefee, J., Busch, R., Miller, A., Ahmed, A., Arif, A., Lee, J., Desai, S., Bansal, S., Bentsianov, M., Belledonne, M., Jere, C., Gaona, R., Greenwood, G., Brusco, O., Boiskin, M., Belo, D., Minasian, R., Atray, N., Lawrence, M., Taliercio, J., Pergola, P., Scott, D., Alvarez, G., Marder, B., Powell, T., Bakdash, W., Stoica, G., Mcfadden, C., Rendell, M., Wise, J., Jones, A., Jardula, M., Madu, I. -J., Varghese, F., Tulloch, B., Ahmed, Z., Hames, M., Nazeer, I., Shahid, N., John, R., Montero, M., Fitz-Patrick, D., Phillips, L., Guasch, A., Christofides, E., Gundroo, A., Amin, M., Bowman-Stroud, C., Link, M., Mulloy, L., Nammour, M., Lalwani, T., Hanson, L., Whaley-Connell, A., Herman, L., Chatha, R., Osama, S., Liss, K., Kayali, Z., Bhargava, A., Israel, E., Peguero-Rivera, A., Fang, M., Slover, J., Barengolts, E., Flores, J., Muoneke, R., Savin, V., Awua-Larbi, S., Levine, A., Newman, G., Golestaneh, L., Bohm, G., Reisin, E., Cruz, L., Weiss, R., Zieve, F., Horwitz, E., Chuang, P., Mersey, J., Manley, J., Graf, R., Bedros, F., Joshi, S., Frias, J., Assefi, A., O'Shaughnessy, A., Brantley, R., Minga, T., Tietjen, D., Kantor, S., Jamal, A., Guadiz, R., Hershon, K., Bressler, P., Kopyt, N., Cathcart, H., Bloom, S., Reichel, R., Nakhle, S., Dulude, E., Tarkan, J., Baker, P., Zeig, S., Moya Hechevarria, J., Ropero-Cartier, A., De la Calle, G., Doshi, A., Saba, F., Sligh, T., Shaw, S., Kumar, J., Szerlip, H., Bayliss, G., Perlman, A., Sakhrani, L., Gouge, S., Argoud, G., Acosta, I., Elder, J., Sensenbrenner, J., Vicks, S., Mangoo-Karim, R., Galphin, C., Leon-Forero, C., Gilbert, J., Brown, E., Ijaz, A., Butt, S., Markell, M., Arauz-Pacheco, C., Sloan, L., Alvarado, O., Jabbour, S., Simon, E., Rastogi, A., James, S., Hall, K., Melish, J., Dixon, B., Adolphe, A., Kovesdy, C., Beddhu, S., Solomon, R., Fernando, R., Levin, E., Thakar, C., Robey, B., Goldfarb, D., Fried, L., Maddukuri, G., Thomson, S., Annand, A., Kronfli, S., Kalirao, P., Schmidt, R., Dahl, N., Blumenthal, S., Weinstein, D., Ostergaard, O., Weinstein, T., Ono, Y., Yalcin, M., Karim, S., Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, and Diabetes Clinic
- Subjects
Male ,endothelin ,albuminuria ,nephropathy ,inhibition ,Diabetes Mellitus, Type 2/drug therapy ,Endocrinology, Diabetes and Metabolism ,Placebo-controlled study ,Administration, Oral ,030204 cardiovascular system & hematology ,Settore MED/13 - Endocrinologia ,chemistry.chemical_compound ,0302 clinical medicine ,ENDOTHELIN ,80 and over ,Diabetic Nephropathies ,030212 general & internal medicine ,Renal Insufficiency ,Chronic ,Aged, 80 and over ,Diabetic Nephropathies/blood ,General Medicine ,Middle Aged ,Atrasentan/administration & dosage ,Editorial Commentary ,Treatment Outcome ,Nephrology ,Creatinine ,Administration ,young adult ,Female ,medicine.symptom ,Glomerular filtration rate ,Type 2 ,Endothelin A Receptor Antagonists/administration & dosage ,medicine.drug ,Glomerular Filtration Rate ,Human ,Oral ,Adult ,medicine.medical_specialty ,ALBUMINURIA ,Endothelin A Receptor Antagonists ,NEPHROPATHY ,Urology ,INHIBITION ,Renal function ,Serum Albumin, Human ,Placebo ,Nephropathy ,03 medical and health sciences ,Young Adult ,Double-Blind Method ,Atresentan ,diabetes, chronic kidney disease ,medicine ,Diabetes Mellitus ,Aged ,Atrasentan ,Diabetes Mellitus, Type 2 ,Humans ,Renal Insufficiency, Chronic ,Serum Albumin ,business.industry ,Creatinine/blood ,medicine.disease ,Serum Albumin, Human/urine ,n/a OA procedure ,chemistry ,Albuminuria ,Renal Insufficiency, Chronic/blood ,business ,aged, 80 and over ,Kidney disease - Abstract
Background Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.Methods We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18-85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25-75 mL/min per 1.73 m(2) of body surface area, and a urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g who had received maximum labelled or tolerated renin-angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0.75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders) were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0.75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for >= 30 days) or end-stage kidney disease (eGFR = 90 days, chronic dialysis for >= 90 days, kidney transplantation, or death from kidney failure) in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials. gov, number NCT01858532.Findings Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325) or placebo group (n=1323). Median follow-up was 2.2 years (IQR 1.4-2.9). 79 (6.0%) of 1325 patients in the atrasentan group and 105 (7.9%) of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR] 0.65 [95% CI 0.49-0.88]; p=0.0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3.5%) of 1325 patients in the atrasentan group and 34 (2.6%) of 1323 patients in the placebo group (HR 1.33 [95% CI 0.85-2.07]; p=0.208). 58 (4.4%) patients in the atrasentan group and 52 (3.9%) in the placebo group died (HR 1.09 [95% CI 0.75-1.59]; p=0.65).Interpretation Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Copyright (C) 2019 Elsevier Ltd. All rights reserved.
- Published
- 2019
- Full Text
- View/download PDF
18. Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells
- Author
-
Si Hyoung Kim, Sung-Hee Ihm, Seong Jin Lee, Moon Gi Choi, Chul Sik Kim, and Jun Goo Kang
- Subjects
Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Apoptosis ,03 medical and health sciences ,Histone H3 ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,Evodiamine ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Cytotoxic T cell ,Humans ,Viability assay ,Thyroid Neoplasms ,Cytotoxicity ,Chemistry ,Carcinoma ,Drug Synergism ,Antineoplastic Agents, Phytogenic ,Histone Deacetylase Inhibitors ,Trichostatin A ,030220 oncology & carcinogenesis ,Cancer research ,Quinazolines ,Histone deacetylase ,Drug Screening Assays, Antitumor ,Reactive Oxygen Species ,medicine.drug - Abstract
The impact of evodiamine in combination with histone deacetylase (HDAC) inhibitors on survival of thyroid carcinoma cells was identified. TPC-1 and SW1736 human thyroid carcinoma cells were used. After treatment with evodiamine and PXD101, cell viability, the percentage of viable cells and Bcl2 protein levels decreased, whereas cytotoxic activity, the percentage of apoptotic cells, the protein levels of γH2AX, acetyl. histone H3 and cleaved PARP, and reactive oxygen species (ROS) production increased. In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of γH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio. Furthermore, all of the combination index values were
- Published
- 2018
19. Transmasseteric antero-parotid facelift approach for open reduction and internal fixation of condylar fractures
- Author
-
Moon Gi Choi
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Osteosynthesis ,Surgical approach ,business.industry ,medicine.medical_treatment ,Case Report ,Facial nerve ,Condyle ,Parotid gland ,Surgery ,Fixation (surgical) ,stomatognathic diseases ,medicine.anatomical_structure ,stomatognathic system ,Direct exposure ,Condylar fracture ,medicine ,Internal fixation ,Oral Surgery ,business ,Transmasseteric antero-parotid facelift approach - Abstract
Surgical approaches to the condylar fracture include intraoral, preauricular, submandibular, and retromandibular approaches. Each approach has its own advantages and disadvantages. When a patient needs esthetic results and an intraoral approach is not feasible, the transmasseteric antero-parotid facelift approach is considered. This approach permits direct exposure and allow the surgeon to fixate the fractured unit tangentially. Tangential fixation is critical to osteosynthesis. Disadvantages of the transmasseteric antero-parotid facelift approach include damage to the facial nerve and a longer operation time. However, after the initial learning curve, facial nerve damage can be avoided and operation time may decrease. We report three cases of subcondylar fractures that were treated with a transmasseteric antero-parotid facelift approach. Among these, two cases had trivial complications that were easily overcome. Instead of dissecting through the parotid gland parenchyma, the transmasseteric antero-parotid facelift approach uses transmasseteric dissection and reduces facial nerve damage more than the retromandibular transparotid approach. The esthetic result is superior to that of other approaches.
- Published
- 2015
20. Association between metabolic parameters and glomerular hyperfiltration in a representative Korean population without chronic kidney disease
- Author
-
Eun-Gyoung Hong, Moon-Gi Choi, Sangmo Hong, Jae Myung Yu, Doo-Man Kim, Sung-Hee Ihm, and Yun Mi Choi
- Subjects
Male ,Physiology ,Kidney Glomerulus ,030232 urology & nephrology ,Blood Pressure ,030204 cardiovascular system & hematology ,Vascular Medicine ,Biochemistry ,Endocrinology ,0302 clinical medicine ,Chronic Kidney Disease ,Prevalence ,Medicine and Health Sciences ,Diabetic Nephropathies ,Glucose Tolerance ,Alcohol Consumption ,Multidisciplinary ,Middle Aged ,Nutrition Surveys ,Body Fluids ,Blood ,Physiological Parameters ,Nephrology ,Creatinine ,Medicine ,Female ,Anatomy ,Glomerular hyperfiltration ,Glomerular Filtration Rate ,Research Article ,Adult ,medicine.medical_specialty ,Waist ,Endocrine Disorders ,Serum Triglycerides ,Science ,Urology ,Renal function ,Prediabetic State ,03 medical and health sciences ,Diabetes mellitus ,Republic of Korea ,Diabetes Mellitus ,medicine ,Albuminuria ,Humans ,Renal Insufficiency, Chronic ,Triglycerides ,Aged ,Nutrition ,Renal Physiology ,business.industry ,Body Weight ,Biology and Life Sciences ,Odds ratio ,Blood Serum ,medicine.disease ,Diet ,Cross-Sectional Studies ,Metabolism ,Metabolic Disorders ,Microalbuminuria ,business ,Body mass index ,Kidney disease - Abstract
AimsTo investigate associations of glomerular hyperfiltration with other metabolic factors in a nationally representative dataset.MethodsWe analyzed cross-sectional data from 15,918 subjects with estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m2 and urine albumin creation ratio (ACR) ResultsPrevalence of hyperfiltration was 5.2% and that among normal, prediabetic, and diabetic subjects was 4.9%, 5.6%, and 7.3%, respectively, after adjusting for age, sex, and body weight (p for trend = 0.008). In a multiple logistic regression analysis, hyperfiltration was associated with a body mass index ≥30 kg/m2 [odds ratio (OR) = 3.461, pConclusionsIn a general Korean population, both hyperfiltration and ACR were associated with similar metabolic parameters, and hyperfiltration correlated independently with a high ACR. Longitudinal studies are needed to further explore risks of hyperfiltration and microalbuminuria.
- Published
- 2018
21. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
- Author
-
Jun Goo Kang, Hyung Joon Yoo, Si Hyoung Kim, Chul Sik Kim, Sung-Hee Ihm, Seong Jin Lee, and Moon Gi Choi
- Subjects
medicine.medical_specialty ,Cell Survival ,Blotting, Western ,030209 endocrinology & metabolism ,Antineoplastic Agents ,Apoptosis ,Biology ,Wortmannin ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Cell Line, Tumor ,medicine ,Humans ,Viability assay ,Thyroid Neoplasms ,Protein kinase A ,Protein kinase B ,RC254-282 ,Piperidones ,Dipeptidyl-Peptidase IV Inhibitors ,Kinase ,Carcinoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Drug Synergism ,General Medicine ,Isoxazoles ,Resorcinols ,Flow Cytometry ,Adenosine ,Molecular biology ,Gemigliptin ,Endocrinology ,Pyrimidines ,chemistry ,030220 oncology & carcinogenesis ,medicine.drug ,Signal Transduction - Abstract
The effect of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the heat shock protein 90 inhibitor NVP-AUY922 (AUY922) on survival of thyroid carcinoma cells was elucidated. The SW1736 and TPC-1 human thyroid carcinoma cells were used. Cell viability, the percentage of viable cells, cytotoxic activity, the percentage of apoptotic cells, and mitochondrial membrane potential were measured. To evaluate the combined effect of gemigliptin with AUY922, the interactions were estimated by calculating combination index. Gemigliptin led to cell death in conjunction with overexpression of the phosphorylated protein levels of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase. In gemigliptin-treated cells, wortmannin augmented cell death, whereas AZD6244 and compound C did not affect cell survival. Wortmannin decreased phosphorylated adenosine monophosphate–activated protein kinase protein levels, and AZD6244 increased phosphorylated Akt protein levels. Meanwhile, cotreatment of both gemigliptin and AUY922, compared with treatment of AUY922 alone, potentiated cell death. All the combination index values were lower than 1.0, suggesting synergistic cytotoxicity of gemigliptin with AUY922. In treatment of both gemigliptin and AUY922, compared with AUY922 alone, the protein levels of total and phosphorylated Akt, phosphorylated extracellular signal–regulated kinase 1/2, and phosphorylated adenosine monophosphate–activated protein kinase increased without alteration in those of total extracellular signal–regulated kinase 1/2 and total adenosine monophosphate–activated protein kinase. The percentage of apoptotic cells increased. The protein levels of Bax and cleaved poly (ADP-ribose) polymerase increased, whereas Bcl2 protein levels were unchanged, resulting in increment of Bax/Bcl2 ratio. Transfection of Bax small interfering RNA did not cause any variation in cell viability, the percentage of viable cells and cytotoxic activity. Our results demonstrate that gemigliptin exerts a cytotoxic activity with concomitant alterations in expression of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase in thyroid carcinoma cells. Furthermore, gemigliptin synergizes with AUY922 in induction of cytotoxicity via regulation of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase as well as involvement of Bcl2 family proteins in thyroid carcinoma cells.
- Published
- 2017
22. Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells
- Author
-
Hyung Joon Yoo, Moon Gi Choi, Sung-Hee Ihm, Seong Jin Lee, Si Hyoung Kim, Chul Sik Kim, and Jun Goo Kang
- Subjects
endocrine system diseases ,Cell Survival ,Endocrinology, Diabetes and Metabolism ,Vascular Cell Adhesion Molecule-1 ,030209 endocrinology & metabolism ,Pharmacology ,AMP-Activated Protein Kinases ,Wortmannin ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,Cell Movement ,Cell Line, Tumor ,medicine ,Humans ,Hypoglycemic Agents ,Viability assay ,Thyroid Neoplasms ,Phosphorylation ,Protein kinase A ,Protein kinase B ,Piperidones ,Cell Proliferation ,Membrane Potential, Mitochondrial ,Dipeptidyl-Peptidase IV Inhibitors ,Cell Death ,Dose-Response Relationship, Drug ,Cell growth ,AMPK ,Drug Synergism ,Gemigliptin ,Metformin ,Pyrimidines ,chemistry ,Matrix Metalloproteinase 9 ,030220 oncology & carcinogenesis ,Matrix Metalloproteinase 2 ,medicine.drug ,Signal Transduction - Abstract
The influence of the dipeptidyl peptidase-IV inhibitor, gemigliptin alone or in combination with metformin on survival, proliferation, and migration of thyroid carcinoma cells was investigated. SW1736 and TPC-1 human thyroid carcinoma cells were used. Gemigliptin and metformin caused cell death in a dose-dependent manner. In cells treated with both gemigliptin and metformin, compared with metformin alone, all of the combination index values were lower than 1.0, suggesting synergistic cytotoxicity of two agents. Cell viability, the percentage of viable cells, ATP levels, and mitochondrial membrane potential decreased; however, cytotoxic activity, and the protein levels of cleaved PARP, phospho-Akt and phospho-AMP-activated protein kinase (AMPK) increased. Administration of wortmannin, but not compound C, further decreased cell viability, and further increased cytotoxic activity. Moreover, compared with control, cell proliferation and migration as well as the protein levels of p53, p21, vascular cell adhesion molecule-1 (VCAM-1), and phospho-extracellular signal-regulated kinase (ERK) 1/2 decreased. The decrement of matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels was cell specific. Our results demonstrate that gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells. Furthermore, gemigliptin augments the inhibitory effect of metformin on proliferation and migration through involvement of matrix metalloproteinase-2, matrix metalloproteinase-9, p53, p21, VCAM-1, and ERK in thyroid carcinoma cells.
- Published
- 2017
23. Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells
- Author
-
Si Hyoung Kim, Chul Sik Kim, Seong Jin Lee, Hyung Joon Yoo, Moon Gi Choi, Sung Hee Ihm, and Jun Goo Kang
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Paclitaxel ,Apoptosis ,Thyroid Carcinoma, Anaplastic ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Cytotoxic T cell ,Humans ,Viability assay ,Protein kinase A ,Protein kinase B ,RC254-282 ,Cell Proliferation ,chemistry.chemical_classification ,Reactive oxygen species ,Endoplasmic reticulum ,NF-kappa B ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,Endoplasmic Reticulum Stress ,Triterpenes ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,Oncogene Protein v-akt ,030104 developmental biology ,chemistry ,Proto-Oncogene Proteins c-bcl-2 ,Celastrol ,030220 oncology & carcinogenesis ,Cancer research ,Pentacyclic Triterpenes ,Reactive Oxygen Species - Abstract
The influence of celastrol alone or in combination with paclitaxel on survival of anaplastic thyroid carcinoma cells was investigated. In 8505C and SW1736 cells, after treatment of celastrol, cell viability decreased, and cytotoxic activity increased. The protein levels of heat shock protein (hsp) 90, hsp70, Bax, death receptor 5, cleaved caspase-3, cleaved poly (ADP-ribose) polymerase, phospho-extracellular signal-regulated kinase 1/2 (ERK1/2), and phospho-c-Jun N-terminal kinase (JNK) were elevated, and those of Bcl2, phospho-nuclear factor-kappaB (NF-κB), and total and phospho-Akt were reduced. The endoplasmic reticulum stress markers expression and reactive oxygen species production were enhanced. In celastrol-treated cells, N-acetylcysteine increased cell viability and phospho-NF-κB protein levels, and decreased reactive oxygen species production and cytotoxic activity. The protein levels of cyclooxygenase 2, phospho-ERK1/2, phospho-JNK and Bip were diminished. After treatment of both celastrol and paclitaxel, compared with paclitaxel alone, cell viability and the percentage of viable cells were reduced, and death rate and cytotoxic activity were elevated. The protein levels of phospho-ERK1/2, phospho-JNK, Bip, and cyclooxygenase 2, and reactive oxygen species production were enhanced. All of the Combination Index values calculated by Chou–Talalay equation were lower than 1.0, implying the synergism between celastrol and paclitaxel in induction of cell death. In conclusion, our results suggest that celastrol induces cytotoxicity through involvement of Bcl2 family proteins and death receptor, and modulation of phospho-NF-κB, Akt, and mitogen-activated protein kinase in association with endoplasmic reticulum stress and reactive oxygen species production in anaplastic thyroid carcinoma cells. Moreover, celastrol synergizes with paclitaxel in induction of cytotoxicity in anaplastic thyroid carcinoma cells.
- Published
- 2017
24. Herbimycin A inhibits cell growth with reversal of epithelial–mesenchymal transition in anaplastic thyroid carcinoma cells
- Author
-
Si Hyoung Kim, Sung-Hee Ihm, Seong Jin Lee, Jun Goo Kang, Chul Sik Kim, Hyung Joon Yoo, and Moon Gi Choi
- Subjects
Programmed cell death ,Epithelial-Mesenchymal Transition ,Biophysics ,Vimentin ,Thyroid Carcinoma, Anaplastic ,Biochemistry ,chemistry.chemical_compound ,Downregulation and upregulation ,Antigens, CD ,Cell Movement ,Cell Line, Tumor ,Humans ,Gene Silencing ,Thyroid Neoplasms ,Epithelial–mesenchymal transition ,RNA, Small Interfering ,Molecular Biology ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Cell Proliferation ,Wound Healing ,Cell Death ,biology ,Cell growth ,Cell Biology ,Cadherins ,Flow Cytometry ,Rifabutin ,chemistry ,biology.protein ,Cancer research ,Tumor Suppressor Protein p53 ,Growth inhibition ,Plasmids - Abstract
We aimed to elucidate the effect of herbimycin A (HMA), a heat shock protein 90 inhibitor, on cell growth and epithelial-mesenchymal transition (EMT) in anaplastic thyroid carcinoma (ATC) cells. HMA inhibited cell growth and migration concomitantly with increase of E-cadherin as well as decrease of N-cadherin and vimentin. Moreover, HMA upregulated p21 and p27, while it downregulated p53 and Akt. In HMA-treated condition, knockdown of E-cadherin and overexpression of p53 increased N-cadherin and vimentin, and mitigated the inhibitory effects of HMA on cell growth and migration. Furthermore, knockdown of p21 and p27 ameliorated inhibition of cell growth and reversal of EMT. In addition, the activation of Akt attenuated growth inhibition, cell death and EMT reversal. Therefore, we propose that HMA suppresses cell growth, and reverses EMT in conjunction with the activation of E-cadherin, p21 and p27 and the inactivation of p53 and PI3K/Akt signaling in ATC cells.
- Published
- 2014
- Full Text
- View/download PDF
25. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells
- Author
-
Chul Sik Kim, Sung-Hee Ihm, Seong Jin Lee, Moon Gi Choi, Jun Goo Kang, Hyung Joon Yoo, and Si Hyoung Kim
- Subjects
Programmed cell death ,Paclitaxel ,Cell Survival ,Lactams, Macrocyclic ,Endocrinology, Diabetes and Metabolism ,Antineoplastic Agents ,Cycloheximide ,Thyroid Carcinoma, Anaplastic ,Hsp90 inhibitor ,chemistry.chemical_compound ,Endocrinology ,Cell Line, Tumor ,Benzoquinones ,polycyclic compounds ,Humans ,Medicine ,HSP70 Heat-Shock Proteins ,HSP90 Heat-Shock Proteins ,Thyroid Neoplasms ,Viability assay ,Cell Death ,Caspase 3 ,business.industry ,female genital diseases and pregnancy complications ,Hsp70 ,chemistry ,Cell culture ,Cancer research ,Drug Therapy, Combination ,Growth inhibition ,business - Abstract
The effect of 17-allylamino-17-demethoxygeldanamycin (17-AAG), an hsp90 inhibitor, alone or in combination with paclitaxel on survival of anaplastic thyroid carcinoma (ATC) was evaluated. In 8505C and CAL62 cells, after treatment of 17-AAG, cell viability decreased, and the percentage of dead cells increased. 17-AAG did not cause cleavage of caspase-3 protein, and change expression of IAPs. Pretreatment of z-VAD-fmk did not alter cell viability and the percentage of dead cells. In 17-AAG-treated cells, knockdown of p53 rescued growth inhibition, while cycloheximide attenuated cell death. When cells were treated with both 17-AAG and paclitaxel, all of the combination index values were higher than 1, indicating antagonism between 17-AAG and paclitaxel. In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased. In conclusion, our results suggest that 17-AAG induces non-apoptotic cell death requiring de novo protein synthesis in ATC cells. Moreover, these results demonstrate that 17-AAG antagonizes paclitaxel with concomitant alterations in hsp90 client proteins in ATC cells.
- Published
- 2014
- Full Text
- View/download PDF
26. Unprotected daily sun exposure is differently associated with central adiposity and beta-cell dysfunction by gender: The Korean national health and nutrition examination survey (KNHANES) V
- Author
-
Hyung Joon Yoo, Eun-Gyoung Hong, Doo-Man Kim, In Ho Kwon, Juri Park, Sung-Hee Ihm, Seong Jin Lee, Moon-Gi Choi, Ohk Hyun Ryu, and Jung Hun Ohn
- Subjects
Adult ,Male ,Diabetes risk ,National Health and Nutrition Examination Survey ,Biochemistry ,Young Adult ,Insulin-Secreting Cells ,Environmental health ,Diabetes mellitus ,Republic of Korea ,Diabetes Mellitus ,Prevalence ,Humans ,Medicine ,Obesity ,Adiposity ,General Environmental Science ,Sunlight ,Sex Characteristics ,integumentary system ,business.industry ,Odds ratio ,Middle Aged ,Nutrition Surveys ,medicine.disease ,Central Adiposity ,Female ,Sun exposure ,Insulin Resistance ,business - Abstract
Background Ultraviolet irradiation by sun exposure has been associated with both harms and benefits to metabolic health. Objective The objective of this study was to determine whether unprotected daily sun exposure is associated with the prevalence of diabetes and explore the underlying mechanism. Methods We analyzed the Korean National Health and Nutrition Survey V from 2010 to 2011. Participants 19–60 years of age were asked about the average amount of time they had been exposed to direct sunlight per day since the age of 19. We categorized participants into three groups with different levels of lifetime daily sun exposure and explored the association of sun exposure with the prevalence of diabetes. Results The risk of diabetes was higher in subjects with more than 5 h of unprotected sun exposure per day, with an odds ratio of 2.39 (95% CI 1.75–3.25), compared to those with less than 2 h of sun exposure, and the association remained significant after adjusting for diabetes risk factors. Long-term sun exposure was associated with increased central obesity and the possibility of an increase in visceral adiposity, especially among women, and with decrease in beta cell function and peripheral adiposity or percent body fat in men. Conclusions Our study provides a cutoff for upper limit of sun exposure and suggests unprotected daily sun exposure for more than 5 h should be avoided to prevent diabetes. Increased central adiposity and decreased beta cell function were observed in women and men, respectively, who had long-term unprotected daily sun exposure.
- Published
- 2014
- Full Text
- View/download PDF
27. Trismus Due to Bilateral Coronoid Hyperplasia
- Author
-
Eun Jung Ki, Dong Hyuck Kim, Moon Gi Choi, and Hae Myung Cheon
- Subjects
Genetic inheritance ,Hyperplasia ,business.industry ,Case Report ,Anatomy ,Mandible ,Trismus ,medicine.disease ,Coronoid process ,Mouth opening ,Zygomatic bone ,medicine ,medicine.symptom ,business - Abstract
Bilateral coronoid hyperplasia causes painless progressive trismus, resulting from coronoid process impingement on the posterior aspect of the zygomatic bone. The etiology of coronoid hyperplasia is unclear, with various theories proposed. An endocrine stimulus, increased temporalis activity, trauma, genetic inheritance and familial occurrence have all been proposed, but no substantive evidence exists to support any of these hypotheses. Multiplanar reformatting of axial scans and 3-dimensional reconstruction permit precise reproduction of the shape and size of the coronoid and malar structures, and relationships of all structures of the temporal and infratemporal fossae. This case shows remarkably increased mouth opening by coronoidectomy in a patient who complained of trismus due to hyperplasia of coronoid process.
- Published
- 2014
28. Hyperglycemia as a Potential Prognostic Factor of Idiopathic Sudden Sensorineural Hearing Loss
- Author
-
Chan Hum Park, Moon Gi Choi, Jun Ho Lee, Dong-Kyu Kim, Joong Seob Lee, and Ohk Hyun Ryu
- Subjects
Adult ,Gadolinium DTPA ,Male ,medicine.medical_specialty ,Prognostic factor ,Adolescent ,Hearing Loss, Sensorineural ,Contrast Media ,Oleic Acids ,Gastroenterology ,Prediabetic State ,Impaired glucose tolerance ,Recovery rate ,Internal medicine ,Diabetes mellitus ,Humans ,Medicine ,Prediabetes ,Aged ,Retrospective Studies ,Glycated Hemoglobin ,business.industry ,Retrospective cohort study ,Glucose Tolerance Test ,Middle Aged ,Prognosis ,medicine.disease ,Impaired fasting glucose ,Magnetic Resonance Imaging ,Endocrinology ,Diabetes Mellitus, Type 2 ,Otorhinolaryngology ,Hyperglycemia ,Sudden sensorineural hearing loss ,Female ,Surgery ,business - Abstract
Hyperglycemia is not identified as a significant prognostic factor for idiopathic sudden sensorineural hearing loss in any literature. Therefore, we investigated the prognostic value of hyperglycemia in predicting hearing recovery.A retrospective cohort study.Tertiary university hospital.Patients were classified into 3 groups according to their glucose tolerance using the 75-gram oral glucose tolerance test and hemoglobin A1c test as follows: (1) a normal glucose tolerance group, (2) a prediabetes group, which included patients with impaired glucose tolerance and/or impaired fasting glucose levels, and (3) a diabetes mellitus group.Among 94 patients with idiopathic sudden sensorineural hearing loss, 45 were classified into the normal glucose tolerance group, 28 into the prediabetes group, and 21 into the diabetes mellitus group. The recovery rate of the normal glucose tolerance group was not higher than that of the diabetes mellitus group (P = .140). However, when the prediabetes and diabetes mellitus groups were collectively defined as the impaired glucose regulation (hyperglycemia) group, the hearing recovery rate of the normal glucose tolerance (normoglycemia) group was significantly better than that of the impaired glucose regulation group (P = .038).We suggest that hyperglycemia may be a potential negative prognostic factor for hearing recovery in idiopathic sudden sensorineural hearing loss. Further interventional studies should be followed to determine whether hearing outcomes of the impaired glucose regulation group may be improved to the same extent as those of the normal glucose tolerance group after strict glycemic control.
- Published
- 2014
- Full Text
- View/download PDF
29. A prospective randomized controlled trial of the effects of vitamin D supplementation on long-term glycemic control in type 2 diabetes mellitus of Korea
- Author
-
Sungwha Lee, Moon-Gi Choi, Ohk-Hyun Ryu, Jaemyung Yu, Hyung Joon Yoo, and Franco Mantero
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Parathyroid hormone ,Placebo ,vitamin D deficiency ,chemistry.chemical_compound ,Endocrinology ,Insulin resistance ,Double-Blind Method ,Diabetes mellitus ,Internal medicine ,Republic of Korea ,medicine ,Vitamin D and neurology ,Humans ,Aged ,Cholecalciferol ,Glycemic ,Glycated Hemoglobin ,business.industry ,Middle Aged ,Vitamin D Deficiency ,medicine.disease ,Calcium, Dietary ,Diabetes Mellitus, Type 2 ,chemistry ,Parathyroid Hormone ,Calcium ,Female ,Insulin Resistance ,business - Abstract
Epidemiologic studies have shown that low vitamin D levels are associated with reduced insulin sensitivity and increased risk of developing type 2 diabetes mellitus (T2DM). However, there is little evidence that vitamin D supplementation improves glucose intolerance. We evaluated the glucose-lowering effect of vitamin D in Korean T2DM subjects. We enrolled 158 T2DM patients who had stable glycemic control [hemoglobin A1c (HbA1c)
- Published
- 2014
- Full Text
- View/download PDF
30. Frey Syndrome after Retromandibular Approach for Condyle Fracture Reduction
- Author
-
Jae-Min Lee, Moon-Gi Choi, Hae-Myung Cheon, and Eun-Jung Ki
- Subjects
medicine.medical_specialty ,Sympathetic Fibers ,business.industry ,Male patient ,medicine ,Auriculotemporal nerve ,Degeneration (medical) ,Great auricular nerve ,business ,Condyle ,Gustatory sweating ,Surgery ,Fracture reduction - Abstract
Frey syndrome is a disease characterized by abnormal sweating, facial redness, and rare pain by stimulation of taste sense on the limited area dominated by the auriculotemporal nerve and great auricular nerve. Although the developmental mechanism and histopathologic cause of Frey syndrome are still being debated, the most reliable theory is based on injury of the parathympathetic nerve connected to the auriculotemporal nerve continuing to abnormal regeneration. The other theory is that the sweat glands develop an increased sensitivity after degeneration of sympathetic fibers. Therapy of Frey syndrome includes drugs, radiographic treatment, and surgical treatment; however, in most cases, treatment is not satisfactory. This is a case report on a 24-year-old male patient with Frey syndrome caused by the fracture reduction with retromandibular approach after multiple facial traumas and spontaneous healing without any special treatment.
- Published
- 2013
- Full Text
- View/download PDF
31. Interleukin-1β (IL-1β) increases pain behavior and the blood glucose level: Possible involvement of glucocorticoid system
- Author
-
Hong-Won Suh, Soo-Hyun Park, Moon-Gi Choi, Ohk-Hyun Ryu, Seong-Soo Choi, Yun-Beom Sim, Yu-Jung Kang, and Jun-Sub Jung
- Subjects
Blood Glucose ,Male ,Nociception ,medicine.medical_specialty ,Pituitary gland ,Corticotropin-Releasing Hormone ,medicine.medical_treatment ,Interleukin-1beta ,Immunology ,Pain ,Biochemistry ,Mice ,Hormone Antagonists ,Receptors, Glucocorticoid ,Internal medicine ,Adrenal Glands ,medicine ,Animals ,Immunology and Allergy ,RNA, Messenger ,Molecular Biology ,Mice, Inbred ICR ,Adrenal gland ,business.industry ,Adrenalectomy ,Hematology ,Spinal cord ,Mifepristone ,Glucose ,medicine.anatomical_structure ,Endocrinology ,Spinal Cord ,Hypothalamus ,Pituitary Gland ,Corticosterone ,business ,Proto-Oncogene Proteins c-fos ,Glucocorticoid ,Hormone ,medicine.drug - Abstract
The possible involvement of glucocorticoid system in interleukin-1β (IL-1β)-induced nociception and the blood glucose level was studied in ICR mice. In the first experiment, mice were treated intrathecally (i.t.) with IL-1β (100 pg). Corticotrophin releasing hormone (CRH) mRNA (hypothalamus) and c-Fos mRNA (pituitary gland, spinal cord, and the adrenal gland) levels were measured at 30, 60 and 120 min after IL-1β administration. We found that i.t. injection with IL-1β increased CRH mRNA level in the hypothalamus. The IL-1β administered i.t. elevated c-Fos mRNA levels in the spinal cord, pituitary and adrenal glands. Furthermore, i.t. administration of IL-1β significantly increased the plasma corticosterone level up to 60 min. In addition, the adrenalectomy caused the reductions of the blood glucose level and pain behavior induced by IL-1β injected i.t. in normal and D -glucose-fed groups. Furthermore, intraperitoneal (i.p.) pretreatment with RU486 (100 mg/kg) attenuated the blood glucose level and pain behavior induced by IL-1β administered i.t. in normal and D -glucose-fed groups. Our results suggest that IL-1β administered i.t. increases the blood glucose level and pain behavior via an activation of the glucocorticoid system.
- Published
- 2013
- Full Text
- View/download PDF
32. Gestational hyperlipidemia and acute pancreatitis with underlying partial lipoprotein lipase deficiency and apolipoprotein E3/E2 genotype
- Author
-
Hyung Joon Yoo, In Ho Moh, Doo-Man Kim, Eun-Gyoung Hong, Moon-Gi Choi, Dong Hee Han, and Sung Hee Ihm
- Subjects
Apolipoprotein E ,Adult ,medicine.medical_specialty ,Apolipoprotein B ,Apolipoprotein E2 ,Apolipoprotein E3 ,Case Report ,Hyperlipidemias ,Lipoprotein lipase deficiency ,Apolipoproteins E ,Pregnancy ,Recurrence ,Internal medicine ,Hyperlipidemia ,Fatty Acids, Omega-3 ,Medicine ,Humans ,Genetic Predisposition to Disease ,Diet, Fat-Restricted ,Lipoprotein lipase ,biology ,business.industry ,nutritional and metabolic diseases ,medicine.disease ,Combined Modality Therapy ,Lipids ,Pregnancy Complications ,Endocrinology ,Phenotype ,Treatment Outcome ,Pancreatitis ,Acute Disease ,biology.protein ,Acute pancreatitis ,Fluid Therapy ,lipids (amino acids, peptides, and proteins) ,Female ,Hyperlipoproteinemia Type I ,Parenteral Nutrition, Total ,business ,Tomography, X-Ray Computed ,Biomarkers - Abstract
We report the case of a patient who experienced extreme recurrent gestational hyperlipidemia. She was diagnosed with partial lipoprotein lipase (LPL) deficiency but without an associated LPL gene mutation in the presence of the apolipoprotein E3/2 genotype. This is the first reported case of extreme gestational hyperlipidemia with a partial LPL deficiency in the absence of an LPL gene mutation and the apolipoprotein E 3/2 genotype. She was managed with strict dietary control and medicated with omega-3 acid ethyl esters. A patient with extreme hyperlipidemia that is limited to the gestational period should be considered partially LPL-deficient. Extreme instances of hyperlipidemia increase the risk of acute pancreatitis, and the effect of parturition on declining plasma lipid levels can be immediate and dramatic. Therefore, decisions regarding the timing and route of delivery with extreme gestational hyperlipidemia are critical and should be made carefully.
- Published
- 2013
33. Effect of GABA Receptor Agonists or Antagonists Injected Spinally on the Blood Glucose Level in Mice
- Author
-
Hong-Won Suh, Soo-Hyun Park, Ohk-Hyun Ryu, Moon-Gi Choi, Yu-Jung Kang, Su-Jin Kim, Yun-Beom Sim, Chea-Ha Kim, Sung-Su Kim, and Jun-Sub Jung
- Subjects
Blood Glucose ,Male ,Agonist ,Baclofen ,medicine.medical_specialty ,medicine.drug_class ,GABAB receptor ,Biochemistry ,Mice ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Phaclofen ,Receptors, GABA ,GABA receptor ,Internal medicine ,medicine ,Animals ,Injections, Spinal ,Mice, Inbred ICR ,GABAA receptor ,General Medicine ,Bicuculline ,Endocrinology ,nervous system ,chemistry ,Muscimol ,medicine.drug - Abstract
The possible roles of gamma-amino butyric acid (GABA) receptors located in the spinal cord for the regulation of the blood glucose level were studied in ICR mice. We found in the present study that intrathecal (i.t.) injection with baclofen (a GABAB receptor agonist; 1-10 μg/5 μl) or bicuculline (a GABAA receptor antagonist; 1-10 μg/5 μl) caused an elevation of the blood glucose level in a dose-dependent manner. The hyperglycemic effect induced by baclofen was more pronounced than that induced by bicuculline. However, muscimol (a GABAA receptor agonist; 1-5 μg/5 μl) or phaclofen (a GABAB receptor antagonist; 5-10 μg/5 μl) administered i.t. did not affect the blood glucose level. Baclofen-induced elevation of the blood glucose was dose-dependently attenuated by phaclofen. Furthermore, i.t. pretreatment with pertussis toxin (PTX; 0.05 or 0.1 μg/5 μl) for 6 days dose-dependently reduced the hyperglycemic effect induced by baclofen. Our results suggest that GABAB receptors located in the spinal cord play important roles for the elevation of the blood glucose level. Spinally located PTX-sensitive G-proteins appear to be involved in hyperglycemic effect induced by baclofen. Furthermore, inactivation of GABAA receptors located in the spinal cord appears to be responsible for tonic up-regulation of the blood glucose level.
- Published
- 2013
- Full Text
- View/download PDF
34. Advantages of intraoral and transconjunctival approaches for posterior displacement of a fractured zygomaticomaxillary complex
- Author
-
Won Jong Park, Seung Jae Paek, Moon-Gi Choi, Kyung-Hwan Kwon, Eun Joo Choi, Jang Won Lee, and Ji Yong Yoo
- Subjects
Orthodontics ,medicine.medical_specialty ,Displacement direction ,business.industry ,Research ,Posterior displacement ,medicine.medical_treatment ,Surgical approach ,Dentistry ,030230 surgery ,Hospital records ,Computed tomographic ,03 medical and health sciences ,Plastic surgery ,0302 clinical medicine ,Oral and maxillofacial surgery ,Medicine ,Transconjunctival approach ,Displacement (orthopedic surgery) ,030223 otorhinolaryngology ,business ,Zygomaticomaxillary complex (ZMC) fracture ,Reduction (orthopedic surgery) - Abstract
Background Fracture of the zygomaticomaxillary complex (ZMC) is one of the most common facial injuries. A previous study has performed 3D analyses of the parallel and rotational displacements that occur in a fractured ZMC. However, few studies have investigated adequate fixation methods according to these displacements. Here, we assessed whether specific approaches and fixation methods for displacement of ZMC fractures produce esthetic results. Methods Hospital records and pre- and post-surgical computed tomographic scans of patients treated for ZMC fractures at the Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University, between January 2010 and December 2015, were selected. Data were analyzed according to the direction of displacement and post-reduction prognosis using a 3D software. Results With ZMC fractures, displacement in the posterior direction occurred most frequently, while displacement in the superior-inferior direction was rare. A reduction using a transconjunctival approach and an intraoral approach was statistically better than that using an intraoral approach, Gillies approach, and lateral canthotomy approach for a posterior displacement (P
- Published
- 2016
- Full Text
- View/download PDF
35. Changes of lip morphology following mandibular setback surgery using 3D cone-beam computed tomography images
- Author
-
Eun Joo Choi, Seung Jae Paek, Ji Yong Yoo, Moon Gi Choi, Young Deok Chee, Jang Won Lee, Won-Jong Park, and Kyung-Hwan Kwon
- Subjects
Cone beam computed tomography ,medicine.medical_specialty ,Mandibular setback surgery ,Morphology (linguistics) ,medicine.medical_treatment ,Lower lip ,Orthognathic surgery ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,Class III malocclusion ,Medicine ,030223 otorhinolaryngology ,Lip morphology ,Orthodontics ,business.industry ,Class iii malocclusion ,Projection angle ,Research ,030206 dentistry ,Plastic surgery ,stomatognathic diseases ,Cheilion ,Three-dimensional evaluation ,business - Abstract
Background The aims of this study are to evaluate the lip morphology and change of lip commissure after mandibular setback surgery (MSS) for class III patients and analyze association between the amount of mandibular setback and change of lip morphology. Methods The samples consisted of 14 class III patients treated with MSS using bilateral sagittal split ramus osteotomy. Lateral cephalogram and cone-beam CT were taken before and about 6 months after MSS. Changes in landmarks and variables were measured with 3D software program Ondemand™. Paired and independent t tests were performed for statistical analysis. Results Landmarks in the mouth corner (cheilion, Ch) moved backward and downward (p < .005, p < .01). However, cheilion width was not statistically significantly changed. Landmark in labrale superius (Ls) was not altered significantly. Upper lip prominence angle (ChRt-Ls-ChLt °) became acute. Landmarks in stomion (Stm), labrale inferius (Li) moved backward (p < .005, p < .001). Lower lip prominence angle (ChRt-Li-ChLt °) became obtuse (p < .001). Height of the upper and lower lips was not altered significantly. Length of the upper lip vermilion was increased (p =< 0.01), and length of the lower lip vermilion was decreased (p < .05). Lip area on frontal view was not statistically significantly changed, but the upper lip area on lateral view was increased and change of the lower lip area decreased (p > .05, p < .005). On lateral view, upper lip prominent point (UP) moved downward and stomion moved backward and upward and the angle of Ls-UP-Stm (°) was decreased. Lower lip prominent point (LP) moved backward and downward, and the angle of Stm-LP-Li (°) was increased. Li moved backward. Finally, landmarks in the lower incisor tip (L1) moved backward and upward, but stomion moved downward. After surgery, lower incisor tip (L1) was positioned more superiorly than stomion (p < .05). There were significant associations between horizontal soft tissue and corresponding hard tissue. The posterior movement of L1 was related to statistically significantly about backward and downward movement of cheilion. Conclusions The lip morphology of patients with dento-skeletal class III malocclusion shows a significant improvement after orthognathic surgery. Three-dimensional lip morphology changes in class III patients after MSS exhibited that cheilion moved backward and downward, upper lip projection angle became acute, lower lip projection angle became obtuse, change of upper lip area on lateral view was increased, change of lower lip area decreased, and morphology of lower lip was protruding. L1 was concerned with the lip tissue change in statistically significant way.
- Published
- 2016
36. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells
- Author
-
Chul Sik Kim, Jun Goo Kang, Hyung Joon Yoo, Si Hyoung Kim, Moon Gi Choi, Sung-Hee Ihm, and Seong Jin Lee
- Subjects
0301 basic medicine ,Cell Survival ,Pyridines ,Survivin ,Apoptosis ,Inhibitor of apoptosis ,Inhibitor of Apoptosis Proteins ,Thyroid carcinoma ,03 medical and health sciences ,chemistry.chemical_compound ,Phosphatidylinositol 3-Kinases ,0302 clinical medicine ,Cell Line, Tumor ,Humans ,Viability assay ,HSP90 Heat-Shock Proteins ,Thyroid Neoplasms ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Pharmacology ,Adenine ,TOR Serine-Threonine Kinases ,NF-kappa B ,Drug Synergism ,General Medicine ,Triptolide ,Phenanthrenes ,XIAP ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Cancer research ,Epoxy Compounds ,Diterpenes ,Proto-Oncogene Proteins c-akt ,DNA Damage ,Signal Transduction - Abstract
The effec.t of BIIB021, a novel heat shock protein 90 (hsp90) inhibitor, on survival of thyroid carcinoma cells has not been evaluated. In this study, the impact of BIIB021 alone or in combination with the histone acetyltransferase inhibitor triptolide on survival of thyroid carcinoma cells was identified. In 8505C and TPC-1 thyroid carcinoma cells, BIIB021 caused cell death in conjunction with alterations in expression of hsp90 client proteins. Cotreatment of both BIIB021 and triptolide, compared with treatment of BIIB021 alone, decreased cell viability, and increased the percentage of dead cells and cytotoxic activity. All of the combination index values were lower than 1.0, suggesting synergistic activity of BIIB021 with triptolide in induction of cytotoxicity. In treatment of both BIIB021 and triptolide, compared with treatment of BIIB021 alone, the protein levels of total and phospho-p53, and cleaved caspase-3 were elevated, while those of total Akt, phospho-mTOR, phospho-4EBP1, phospho-S6K, phospho-NF-κB, survivin, X-linked inhibitor of apoptosis protein (xIAP), cellular inhibitor of apoptosis protein (cIAP) and acetyl. histone H4 were reduced. These results suggest that BIIB021 has a cytotoxic activity accompanied by regulation of hsp90 client proteins in thyroid carcinoma cells. Moreover, the synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-κB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells.
- Published
- 2016
37. Various pain stimulations cause an increase of the blood glucose level
- Author
-
Jun-Sub Jung, Hong-Won Suh, Moon-Gi Choi, Ohk-Hyun Ryu, Soo-Hyun Park, Yu-Jung Kang, and Yun-Beom Sim
- Subjects
medicine.medical_specialty ,Glutamate receptor ,Normal level ,Substance P ,Stimulation ,Intrathecal ,General Biochemistry, Genetics and Molecular Biology ,chemistry.chemical_compound ,Acetic acid ,Endocrinology ,chemistry ,Biochemistry ,Internal medicine ,medicine ,Animal Science and Zoology ,Icr mice - Abstract
The relationship between pain stimulation and the blood glucose level was studied in ICR mice. We examined the possible change of the blood glucose level after the pain stimulation induced by acetic acid injected intraperitoneally (i.p.),, formalin injected subcutaneously (s.c.) into the hind paw, or substance P (SP), glutamate, and pro-inflammatory cytokines (TNF-α and IFN-γ) injected intrathecally (i.t.). We found in the present study that acetic acid, formalin, SP, TNF-α, and IFN-γ increased the blood glucose level. The blood glucose level reached at maximal state 30 min and returned to normal level 2 h after the pain stimulation in a fasting group. Furthermore, acetic acid, formalin, SP, TNF-α, and IFN-γ caused the elevation of the blood glucose level in d-glucose-fed group only in an additive manner. However, i.t. injection of glutamate did not alter the blood glucose level in a fasting group. In contrast, i.t. injection of glutamate enhanced the blood glucose level in the d-glucose-fed grou...
- Published
- 2012
- Full Text
- View/download PDF
38. Central anti-diabetic action of biguanide and thizolidinediones in d-glucose fed and streptozotocin-treated mouse models
- Author
-
Ohk-Hyun Ryu, Sung-Su Kim, Jun-Sub Jung, Yu-Jung Kang, Chea-Ha Kim, Hong-Won Suh, Yun-Beom Sim, Moon-Gi Choi, Su-Jin Kim, and Soo-Hyun Park
- Subjects
Blood Glucose ,medicine.medical_specialty ,endocrine system diseases ,medicine.drug_class ,Biguanides ,Streptozocin ,Diabetes Mellitus, Experimental ,Rosiglitazone ,Mice ,chemistry.chemical_compound ,D-Glucose ,Internal medicine ,Diabetes mellitus ,medicine ,Animals ,Hypoglycemic Agents ,Thiazolidinedione ,Injections, Spinal ,Injections, Intraventricular ,Mice, Inbred ICR ,Pioglitazone ,Biguanide ,business.industry ,General Neuroscience ,Brain ,nutritional and metabolic diseases ,Streptozotocin ,medicine.disease ,Metformin ,Glucose ,Endocrinology ,Diabetes Mellitus, Type 2 ,chemistry ,Thiazolidinediones ,business ,medicine.drug - Abstract
Background In the present study, the possible anti-diabetic action of biguanide and thiazolidinediones administered supraspinally or spinally was studied in ICR mice. Methods Mice were intracerebroventricular (i.c.v.) or intrathecal (i.t.) treated with 20 or 30 μg metformin, pioglitazone and rosiglitazone in d -glucose fed and streptozotocin-treated models, and blood glucose levels was measured at 30, 60 and 120 min after i.c.v. or i.t. administration. Results We found that i.c.v. injection with metformin or rosiglitazone slightly attenuated the blood glucose level in d -glucose fed model, whereas pioglitazone showed no effect on the blood glucose level in d -glucose fed model. The i.t. administration with metformin, pioglitazone or rosiglitazone did not alter the blood glucose level in d -glucose fed model. We also assessed the possible roles of biguanide and thiazolidinedione in the regulation of the blood glucose level in streptozotocin-treated model. We found in the present study that i.c.v. or i.t. administration with metformin caused a pronounced attenuation of the blood glucose level in streptozotocin-treated model. However, rosiglitazone administered i.c.v. did not affect the blood glucose level in streptozotocin-treated model. Conclusions Our results suggest that the anti-diabetic actions of metformin and rosiglitazone appear to be mediated via the brain regions as revealed in d -glucose fed animal model. Furthermore, metformin administered supraspinally or spinally may be effective for treating type I diabetes mellitus as revealed in streptozotocin-treated mouse model.
- Published
- 2012
- Full Text
- View/download PDF
39. Interleukin‐1β (IL‐1β) increases pain behavior and the blood glucose level: Possible involvement of sympathetic nervous system
- Author
-
Yu-Jung Kang, Hong-Won Suh, Soo-Hyun Park, Moon-Gi Choi, Yun-Beom Sim, Ohk-Hyun Ryu, and Jun-Sub Jung
- Subjects
Blood Glucose ,Male ,Nociception ,medicine.medical_specialty ,Sympathetic nervous system ,Sympathetic Nervous System ,Interleukin-1beta ,Clinical Biochemistry ,Pain ,Toxicology ,Biochemistry ,Mice ,Behavioral Neuroscience ,Phentolamine ,Internal medicine ,medicine ,Animals ,Injections, Spinal ,Biological Psychiatry ,Pain Measurement ,Metoprolol ,Pharmacology ,Mice, Inbred ICR ,Behavior, Animal ,Tyrosine hydroxylase ,business.industry ,Antagonist ,Up-Regulation ,Yohimbine ,Endocrinology ,medicine.anatomical_structure ,Catecholamine ,business ,medicine.drug - Abstract
The relationship between interleukin-1β (IL‐1β)‐induced nociception and the blood glucose level was studied in ICR mice. We found in the present study that intrathecal (i.t.) injection of IL‐1β increased pain behavior. In addition, i.t. IL‐1β injection caused an elevation of the blood glucose level. The time‐course study showed that maximal blood glucose level was observed 30 and 60 min after i.t. IL‐1β administration. Furthermore, i.t. injection of IL‐1β enhanced the blood glucose level when mice were orally fed with d ‐glucose. The i.t. administration of IL‐1β antagonist (AF12198) inhibited the hyperglycemia and pain behaviors induced by IL‐1β. We found in the present study that adrenal tyrosine hydroxylase (TH) mRNA level was also increased by i.t. IL‐1β injection. Furthermore, intraperitoneal (i.p.) pretreatment with phentolamine (an α1‐adrenergic blocker) or yohimbine (an α2‐adrenergic blocker) significantly attenuated the blood glucose level and pain behavior induced by IL‐1β administered i.t. However, the blood glucose level and pain behavior were not affected by butoxamine (a β2-adrenergic blocker), whereas metoprolol (a β2-adrenergic blocker) enhanced IL‐1β-induced blood glucose level and pain behavior in mice fed with d ‐glucose. However, its effect was not statistically significant. Our results suggest that IL‐1β administered i.t. increases the blood glucose level via an activation of α adrenergic nervous system.
- Published
- 2012
- Full Text
- View/download PDF
40. Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?
- Author
-
Eun Gyung Hong, Doo-Man Kim, Sung Hee Ihm, Seong Jin Lee, Ohk Hyun Ryu, Jun Goo Kang, So Young Park, Moon Gi Choi, Chul Sik Kim, Sung Hoon Yu, Jae Myung Yoo, Hyung Joon Yoo, and Hyeon Kyu Kim
- Subjects
Carotid atherosclerosis ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Carotid arteries ,Confounding ,nutritional and metabolic diseases ,Diabetes mellitus, type 2 ,Type 2 diabetes ,medicine.disease ,Independent predictor ,musculoskeletal system ,Diabetes mellitus ,Internal medicine ,medicine ,Cardiology ,cardiovascular system ,Original Article ,cardiovascular diseases ,Risk factor ,Glycemic variability ,business ,Glycemic - Abstract
BACKGROUND Little is known about the relative contribution of long-term glycemic variability to the risk of macrovascular complications in type 2 diabetes. This study was conducted to evaluate the effect of A1C variability on the progression of carotid artery intima-media thickness (IMT) in type 2 diabetic patients. METHODS Among type 2 diabetic patients who visited Hallym University Sacred Heart Hospital from March 2007 to September 2009, 120 patients who had carotid artery IMT measured annually and A1C checked every three months for at least one year were analyzed. Individual A1C variability was defined as the standard deviation (SD) of five A1C levels taken every three months for approximately one year. Change in IMT was defined as an increase in IMT on follow-up measurement. The association between the SD of A1C and changes in IMT was evaluated. RESULTS With greater A1C variability, there was a greater increase in the mean IMT (r = 0.350, P < 0.001) of the carotid artery. After adjusting for confounding factors that may influence IMT, A1C variability was significantly associated with the progression of IMT (r = 0.222, P = 0.034). However, the SD of A1C was not a significant independent risk factor for the progression of IMT in multiple regression analysis (beta = 0.158, P = 0.093). CONCLUSION Higher A1C variability is associated with IMT progression in type 2 diabetic patients; however, it is not an independent predictor of IMT progression. Overall glycemic control is the most important factor in the progression of IMT.
- Published
- 2010
41. Effects of α-lipoic acid on transforming growth factor β1–p38 mitogen-activated protein kinase–fibronectin pathway in diabetic nephropathy
- Author
-
Ohk Hyun Ryu, Sung-Hee Ihm, Seong Jin Lee, Chul Sik Kim, Tae Wha Kim, Jun Goo Kang, Dong-Sun Kim, Moon Gi Choi, and Hyung Joon Yoo
- Subjects
Blood Glucose ,Male ,MAPK/ERK pathway ,medicine.medical_specialty ,Rats, Inbred OLETF ,Endocrinology, Diabetes and Metabolism ,p38 mitogen-activated protein kinases ,Renal cortex ,Blotting, Western ,Fatty Acids, Nonesterified ,p38 Mitogen-Activated Protein Kinases ,Antioxidants ,Transforming Growth Factor beta1 ,Diabetic nephropathy ,Random Allocation ,chemistry.chemical_compound ,Endocrinology ,Malondialdehyde ,Internal medicine ,medicine ,Animals ,Insulin ,Diabetic Nephropathies ,Aspartate Aminotransferases ,Phosphorylation ,Protein kinase A ,Glycated Hemoglobin ,Thioctic Acid ,biology ,business.industry ,Alanine Transaminase ,medicine.disease ,Fibronectins ,Rats ,Specific Pathogen-Free Organisms ,Fibronectin ,Proteinuria ,Lipoic acid ,Cholesterol ,medicine.anatomical_structure ,chemistry ,biology.protein ,business ,Signal Transduction ,Transforming growth factor - Abstract
In diabetic nephropathy, transforming growth factor beta1 (TGFbeta1) is related to p38 mitogen-activated protein kinase (MAPK) that induces production of fibronectin in mesangial cells. We investigated the effects of alpha-lipoic acid (ALA), a potent antioxidant, on proteinuria and TGFbeta1-p38 MAPK-fibronectin pathway in diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. After ALA treatment for 5 weeks in OLETF rats at 30 weeks of age, plasma malondialdehyde, urinary protein excretion, renal cortical TGFbeta1, and fibronectin protein levels were decreased; and urinary protein excretion was positively correlated with renal cortical TGFbeta1 and fibronectin protein levels. Phospho-form but not total-form levels as well as fold activations of each protein consisting of p38 MAPK pathway were also attenuated. These results suggest that ALA ameliorates proteinuria by attenuating expressions of TGFbeta1 and fibronectin proteins, and these favorable effects are related to inhibition of phosphorylating activation of p38 MAPK pathway in renal cortex of OLETF rats.
- Published
- 2009
- Full Text
- View/download PDF
42. Related Factors with Decreased Physical Function in the Community-Dwelling Elderly in Chuncheon: Hallym Aging Study(HAS)
- Author
-
Sang Kon Lee, Dong-Hyun Kim, Hyun-Ah Kim, Jin-Young Jeong, Young Ho Choi, Sun Ae Jeon, Seok Won Park, Kyung Soon Hong, and Moon Gi Choi
- Subjects
Related factors ,Gerontology ,business.industry ,Medicine ,Physical function ,business ,Socioeconomic status - Published
- 2008
- Full Text
- View/download PDF
43. Current status of diabetes management in elderly Koreans with diabetes
- Author
-
Hak Yun Bae, In Kyung Jeong, Jung Hyun Noh, Hak Chul Jang, Young Jung Cho, Hong Uoo Nam, Hyung Joon Yoo, In-Ju Kim, Moon Gi Choi, Su Kyung Kim, and Yoo Hun Ahn
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Health Status ,Endocrinology, Diabetes and Metabolism ,Type 2 diabetes ,Endocrinology ,Patient Education as Topic ,Diabetes management ,Internal medicine ,Diabetes mellitus ,Diabetes Mellitus ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Exercise ,Stroke ,Aged ,Glycemic ,Korea ,business.industry ,Blood Glucose Self-Monitoring ,General Medicine ,medicine.disease ,Health Surveys ,Blood pressure ,Physical therapy ,Female ,business ,Body mass index ,Dyslipidemia - Abstract
Knowledge about the current status of diabetes management is indispensable for the improvement of diabetes management. We performed a survey to investigate the current trend of diabetes management in elderly Koreans, at eight hospitals located throughout the country. A total of 539 patients with type 2 diabetes older than 65 years (men=224, women=315) were recruited. Their mean age was 71.5+/-4.9 years and BMI 24.3+/-3.4 (men=23.6+/-2.8, women=24.9+/-3.7)kg/m(2), and 38.2% of the patients were obese (BMIor =25 kg/m(2), men=29.5%, women=44.4%). The mean duration of the diabetes was 13.1+/-9.2 years. Although 37.3% of the patients had A1C below 7.0%, 33.8% of the patients had A1C more than 8.0%. Three hundred and sixty three patients (67.4%) were treated with oral hypoglycemic agents and 175 patients (32.5%) were treated with insulin or combination with oral agents. The glycemic control was better in patients treated with oral agents (oral agent group=7.7+/-4.6%, insulin group=8.5+/-1.9%). Although mean SBP and DBP were 131.4+/-16.7 and 75.9+/-10.4 mmHg, respectively, 67.4% of the patients had hypertension and 38.2% of the patients with hypertension did not reach the goal (130/80 mmHg). Of 539 elderly patients, 253 patients (47.4%) had dyslipidemia (LDL-Cor =4.1 mmol/l and/or triglycerideor =2.5 mmol/l and/or HDL-C1.1 mmol/l) and 72.7% of the patients with dyslipidemia took the lipid lowering agents. However, 47.4% of them did not achieve the goal (LDL-C2.6 mmol/l and/or triglyceride1.7 mmol/l and/or HDL-C1.1 mmol/l). Twenty-eight patients (5.5%) had been admitted to the hospital because of severe hypoglycemia. Half of the patients (57%) had microvascular complications (retinopathy, neuropathy or overt proteinuria), and 28% of the patients had macro-vascular complications (CVD, stroke or peripheral vascular disease). As elderly diabetic patients are usually polymorbid, diabetes mellitus in old age is needed a more comprehensive approach to not only the treatment of hyperglycemia but also of hypertension, dyslipidemia and other associated diseases.
- Published
- 2007
- Full Text
- View/download PDF
44. Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells
- Author
-
Si Hyoung, Kim, Jun Goo, Kang, Chul Sik, Kim, Sung-Hee, Ihm, Moon Gi, Choi, Hyung Joon, Yoo, and Seong Jin, Lee
- Subjects
TNF-Related Apoptosis-Inducing Ligand ,Cell Line, Tumor ,Cell Culture Techniques ,Humans ,Drug Synergism ,Apigenin ,Thyroid Carcinoma, Anaplastic ,Signal Transduction - Abstract
We studied the effect of apigenin in combination with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on cell survival and the influence of AKT inhibition on the combined effect of apigenin with TRAIL in anaplastic thyroid carcinoma (ATC) cells.The human 8505C and CAL62 ATC cell lines were used.Apigenin in combination with TRAIL, compared to apigenin alone, reduced cell viability and Bcl2 protein levels, elevated the percentage of dead cells, as well as the protein levels of cleaved PARP and phospho-ERK1/2. The protein levels of Bcl-xL, Bax, Bid, total ERK1/2, and total and phospho-AKT were unchanged. Administration of wortmannin further reduced cell viability, and elevated the percentage of dead cells, cytotoxic activity and cleaved PARP protein levels.Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells.
- Published
- 2015
45. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells
- Author
-
Si Hyoung, Kim, Jun Goo, Kang, Chul Sik, Kim, Sung-Hee, Ihm, Moon Gi, Choi, Hyung Joon, Yoo, and Seong Jin, Lee
- Subjects
Antibiotics, Antineoplastic ,Cell Death ,Lactams, Macrocyclic ,Thyroid Carcinoma, Anaplastic ,Gene Expression Regulation, Neoplastic ,Rifabutin ,Cell Line, Tumor ,Benzoquinones ,Humans ,HSP90 Heat-Shock Proteins ,Thyroid Neoplasms ,Proto-Oncogene Proteins c-akt ,beta Catenin ,Signal Transduction - Abstract
The aim of the present study was to evaluate the effect of heat-shock protein 90 (HSP90) inhibitors, 17-allylamino-17-demethoxygeldanamycin (17-AAG) and herbimycin A (HMA) on survival of anaplastic thyroid carcinoma (ATC) cells.Antitumor activities of 17-AAG and HMA were investigated in FRO ATC cells.In FRO ATC cells, 17-AAG and HMA caused cell death with concomitant changes in the expression of HSP90 client proteins, increased β-catenin protein levels, and inhibited PI3K/AKT signaling. The inactivation of β-catenin by β-catenin siRNA transfection and the activation of PI3K/AKT signaling by p110α plasmid transfection abrogated cell death caused by 17-AAG and HMA.17-AAG and HMA have cytotoxic activities accompanied by regulation of HSP90 client proteins, and cytotoxicity is associated with overexpression of β-catenin and suppression of PI3K/AKT signaling in FRO ATC cells.
- Published
- 2015
46. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells
- Author
-
Jun Goo Kang, Si Hyoung Kim, Chul Sik Kim, Hyung Joon Yoo, Sung-Hee Ihm, Seong Jin Lee, and Moon Gi Choi
- Subjects
0301 basic medicine ,Indazoles ,Cell Survival ,Endocrinology, Diabetes and Metabolism ,Glycine ,Antineoplastic Agents ,Apoptosis ,Biology ,Hydroxamic Acids ,Thyroid Carcinoma, Anaplastic ,Histone H4 ,03 medical and health sciences ,Histone H3 ,0302 clinical medicine ,Endocrinology ,Heat shock protein ,Cell Line, Tumor ,Survivin ,medicine ,Humans ,HSP90 Heat-Shock Proteins ,Thyroid Neoplasms ,Phosphorylation ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Vorinostat ,Caspase 3 ,Drug Synergism ,Molecular biology ,Histone Deacetylase Inhibitors ,030104 developmental biology ,Trichostatin A ,030220 oncology & carcinogenesis ,Benzamides ,Cancer research ,Histone deacetylase ,Proto-Oncogene Proteins c-akt ,medicine.drug - Abstract
The influence of the heat shock protein 90 (hsp90) inhibitor SNX5422 alone or in combination with the histone deacetylase (HDAC) inhibitors PXD101, suberoylanilide hydroxamic acid (SAHA), and trichostatin A (TSA) on survival of anaplastic thyroid carcinoma (ATC) cells was investigated. In 8505C and CAL62 cells, SNX5422 caused cell death with concomitant changes in the expression of hsp90 client proteins. After treatment of both SNX5422 and PXD101, SAHA and TSA, compared with treatment of SNX5422 alone, cell viability was diminished, whereas inhibition rate and cytotoxic activity were enhanced. All of the combination index values were lower than 1.0, suggesting the synergism between SNX5422 and PXD101, SAHA and TSA in induction of cell death. In cells treated with both SNX5422 and PXD101, SAHA and TSA, compared with cells treated with SNX5422 alone, the protein levels of Akt, phospho-4EBP1, phospho-S6 K, and survivin were diminished, while those of γH2AX, acetyl. histone H3, acetyl. histone H4, cleaved PARP, and cleaved caspase-3 were enhanced. In conclusion, these results demonstrate that SNX5422 has a cytotoxic activity in conjunction with alterations in the expression of hsp90 client proteins in ATC cells. Moreover, SNX5422 synergizes with HDAC inhibitors in induction of cytotoxicity accompanied by the suppression of PI3K/Akt/mTOR signaling and survivin, and the overexpression of DNA damage-related proteins in ATC cells.
- Published
- 2015
47. Correlation between fasting plasma glucose levels and HbA1c for diagnosis of prediabetes and diabetes: the 2011 Korea National Health and Nutrition Examination Survey
- Author
-
Eun Gyung Hong, Jae Myung Yoo, Doo-Man Kim, Ju Ri Park, Hyung Joon Yoo, Ho Young Son, Moon Gi Choi, Jun Goo Kang, Sung Hoon Yu, Chul Sik Kim, Ohk Hyun Ryu, Sung-Hee Ihm, Seong Jin Lee, and Yoon Jung Kim
- Subjects
medicine.medical_specialty ,Plasma glucose ,National Health and Nutrition Examination Survey ,business.industry ,Internal medicine ,Diabetes mellitus ,medicine ,Prediabetes ,business ,Intensive care medicine ,medicine.disease - Published
- 2015
- Full Text
- View/download PDF
48. Manganese superoxide dismutase gene polymorphism (V16A) is associated with stages of albuminuria in Korean type 2 diabetic patients
- Author
-
Seong Jin Lee, Tae Wha Kim, Dong-Sun Kim, and Moon Gi Choi
- Subjects
Adult ,Male ,Heterozygote ,medicine.medical_specialty ,Genotype ,Endocrinology, Diabetes and Metabolism ,Type 2 diabetes ,Peptidyl-Dipeptidase A ,Biology ,Nephropathy ,Endocrinology ,Gene Frequency ,Risk Factors ,Diabetes mellitus ,Internal medicine ,medicine ,Albuminuria ,Humans ,Allele frequency ,Aged ,Korea ,Polymorphism, Genetic ,Superoxide Dismutase ,Middle Aged ,medicine.disease ,Introns ,Diabetes Mellitus, Type 2 ,Creatinine ,DNA Transposable Elements ,Female ,Microalbuminuria ,Gene polymorphism ,medicine.symptom ,Gene Deletion - Abstract
Several single-nucleotide polymorphisms of genes related to oxidative stress have been evaluated because intracellular reactive oxygen species are associated with development of diabetes and its microvascular complications. We performed a case-control study to investigate whether V16A polymorphism of manganese superoxide dismutase (Mn-SOD) gene is related to pathogenesis of diabetes and whether the polymorphism is associated with stages of albuminuria in Korean type 2 diabetic patients. Genotype distributions were studied in 178 nondiabetic subjects and 371 type 2 diabetic patients of 3 groups with a normoalbuminuria group (Normo group, n = 244), a microalbuminuria group (Micro group, n = 86), and an overt albuminuria group (Macro group, n = 41). The albumin/creatinine ratio (ACR) was defined as a urinary albumin/creatinine ratio. V16A genotypes were determined with polymerase chain reaction-restriction fragment length polymorphism method. Between nondiabetic subjects and type 2 diabetic patients, Mn-SOD genotype distribution (VV/VA + AA, 146/32 vs 314/57) and A allele frequency (0.121 vs 0.104) were not different. Patients with nephropathy, Micro and Macro groups, had significantly lower A allele frequency, longer diabetic duration, higher prevalence of hypertension, and greater ACR than those of patients without nephropathy (P < .05). A allele was significantly less frequent with progression of nephropathy (Normo group, 0.119; Micro group, 0.073; Macro group, 0.03; P < .05). In type 2 diabetic patients, A allele carriers had significantly lower prevalence of hypertension and lesser ACR than those of A allele noncarriers (P < .01). In multivariate analysis, hypertension, duration of diabetes, serum total cholesterol level, and A allele of Mn-SOD gene were independently associated with stages of albuminuria. These results suggest that V16A polymorphism of Mn-SOD gene is not related to pathogenesis of diabetes but is associated with stages of albuminuria in Korean type 2 diabetes.
- Published
- 2006
- Full Text
- View/download PDF
49. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men
- Author
-
Moon Gi Choi, Cheol-Young Park, Sung Woo Park, Moo Il Kang, K.-H. Yoon, Won Young Lee, Ki Hyun Baek, Sung Hee Ihm, Ki Won Oh, Hyung Joon Yoo, Eun-Jung Rhee, and Eun Joo Yun
- Subjects
Adult ,Leptin ,Male ,medicine.medical_specialty ,Peptide Hormones ,Endocrinology, Diabetes and Metabolism ,Adipokine ,Body Mass Index ,Endocrinology ,Waist–hip ratio ,Bone Density ,Internal medicine ,medicine ,Humans ,Resistin ,Triglycerides ,Aged ,Bone mineral ,Lumbar Vertebrae ,Estradiol ,Adiponectin ,Femur Neck ,Waist-Hip Ratio ,business.industry ,Body Weight ,Age Factors ,Middle Aged ,Ghrelin ,Cholesterol ,Hormones, Ectopic ,Intercellular Signaling Peptides and Proteins ,business ,Body mass index - Abstract
Body weight is a significant predictor of bone mass. Hormonal factors such as sex hormones, insulin, leptin and adiponectin are thought to play a role in the mechanisms controlling the association of body weight and fat mass with bone mass. However, contradictory results have been reported for the association between serum adipocytokines and bone mineral density (BMD). We therefore examined whether the serum adipocytokine and ghrelin levels, markers of fat metabolism, are associated with BMD in male adults.For 80 male adults (average age 54.5 +/- 6.4 years; average body mass index (BMI) 24.4 +/- 2.5 kg/m2), the correlations between serum resistin, leptin, adiponectin and ghrelin levels with BMD were investigated.Among the adipocytokines, serum resistin levels were negatively correlated with lumbar spine BMD (r = -0.237, P = 0.05). After adjustment was made for age and BMI, log-transformed serum leptin showed a significant negative correlation with lumbar spine BMD, which was not seen on bivariate analysis (r = -0.237, P = 0.039). Femoral neck BMD was marginally associated only with serum adiponectin levels (r = -0.226, P = 0.062). In multiple regression analyses, among the adipokines, only resistin was a significant determinant of lumbar spine BMD, although the variance was small (R2 = 0.256). Serum ghrelin levels were not correlated with the BMD of either body site.Serum resistin level showed a significant negative correlation with lumbar spine BMD, although the variance was small. Further studies are needed to elucidate the role of adipocytokines in bone metabolism.
- Published
- 2005
- Full Text
- View/download PDF
50. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males
- Author
-
Eun Joo Yun, Moo Il Kang, Sung Hee Ihm, Hyung Joon Yoo, Sung Woo Park, Won Young Lee, Ki Won Oh, Cheol-Young Park, Moon Gi Choi, Ki Hyun Baek, Sun Woo Kim, and Eun-Jung Rhee
- Subjects
Male ,Aging ,Endocrinology, Diabetes and Metabolism ,Osteoporosis ,Receptors, Cytoplasmic and Nuclear ,Receptors, Tumor Necrosis Factor ,Bone remodeling ,Absorptiometry, Photon ,Endocrinology ,Bone Density ,Medicine ,Testosterone ,Insulin-Like Growth Factor I ,Bone mineral ,Lumbar Vertebrae ,Membrane Glycoproteins ,Estradiol ,Receptor Activator of Nuclear Factor-kappa B ,biology ,Middle Aged ,medicine.anatomical_structure ,RANKL ,Regression Analysis ,Bone Remodeling ,Procollagen ,Adult ,musculoskeletal diseases ,medicine.medical_specialty ,Osteocalcin ,Enzyme-Linked Immunosorbent Assay ,Bone and Bones ,Collagen Type I ,Osteoprotegerin ,Internal medicine ,Humans ,Aged ,Glycoproteins ,Femoral neck ,Korea ,business.industry ,RANK Ligand ,medicine.disease ,Peptide Fragments ,biology.protein ,Carrier Proteins ,Peptides ,business ,Body mass index ,Biomarkers ,Hormone - Abstract
Summary Objective Osteoporosis is a growing health problem in males as well as in females. Sex hormones and insulin-like growth factor-I (IGF-I) have been shown to be the major determinants in male bone metabolism. Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the receptor activator of NF-κB ligand (RANKL). OPG and RANKL have been shown to be important regulators of osteoclastogenesis. However, the relationship between the OPG-RANKL system and male bone status in human populations are unclear. Thus, the aim of this study was to investigate the relationship between the OPG-RANKL system and bone mineral metabolism in males. Patients and Measurements Serum concentrations of OPG, RANKL, oestradiol, total testosterone and IGF-I and bone mineral density (BMD) were measured in 80 Korean males aged 42–70 (mean age, 54·5 year). Enzyme-linked immunosorbent assays were used to determine the serum concentrations of OPG and RANKL. Serum concentrations of oestradiol, total testosterone, IGF-I and bone turnover markers were determined using standard methods. BMD at the lumbar spine and femoral neck were measured by dual energy X-ray absorptiometry. Results We observed a significant negative correlation between the serum OPG levels and lumbar spine BMD (r =−0·259, P
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.